---
document_datetime: 2023-09-21 19:45:54
document_pages: 63
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/nucala-h-c-3860-x-0018-epar-assessment-report-variation_en.pdf
document_name: nucala-h-c-3860-x-0018-epar-assessment-report-variation_en.pdf
version: success
processing_time: 46.4282333
conversion_datetime: 2025-12-20 16:39:49.829617
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
29 May 2019 EMA/341490/2019

## Assessment report on extension(s) of marketing authorisation

Nucala

International non-proprietary name: mepolizumab

Procedure No. EMEA/H/C/003860/X/0018

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 9                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................9   |                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................9                                                |
| 2. Scientific discussion..............................................................................                  | 10                                                                                                       |
| 2.1. Problem statement.............................................................................................     | 10                                                                                                       |
| 2.1.1. Disease or condition                                                                                             | ........................................................................................ 11              |
| 2.1.2. Epidemiology..................................................................................................   | 11                                                                                                       |
| 2.1.3. Biologic features                                                                                                | ............................................................................................. 11         |
| 2.1.4. Clinical presentation, diagnosis                                                                                 | ......................................................................... 11                             |
| 2.1.5. Management...................................................................................................    | 12                                                                                                       |
| 2.2. Quality aspects                                                                                                    | .................................................................................................. 13    |
| 2.2.1. Introduction.................................................................................................... | 13                                                                                                       |
| 2.2.2. Active Substance.............................................................................................    | 14                                                                                                       |
| 2.2.3. Finished Medicinal Product................................................................................       | 17                                                                                                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                      | 20                                                                                                       |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ...................... 20                                                                                |
| 2.2.6. Recommendation(s) for future quality development.............................................                    | 20                                                                                                       |
| 2.3. Non-clinical aspects............................................................................................   | 20                                                                                                       |
| 2.4. Clinical aspects                                                                                                   | ............................................................................................... 20       |
| 2.4.1. Pharmacokinetics                                                                                                 | ........................................................................................ 21              |
| 2.4.2. Pharmacodynamics ......................................................................................          | 29                                                                                                       |
| 2.4.3. Discussion on clinical pharmacology ............................................................                 | 31                                                                                                       |
| 2.4.4. Conclusions on clinical pharmacology                                                                             | .......................................................... 34                                            |
| 2.4.5. Clinical efficacy                                                                                                | ............................................................................................... 34       |
| 2.4.6. Dose response study........................................................................................      | 35                                                                                                       |
| 2.4.7. Main study                                                                                                       | ..................................................................................................... 35 |
| 2.4.8. Discussion on clinical efficacy............................................................................      | 45                                                                                                       |
| 2.4.9. Conclusions on clinical efficacy..........................................................................       | 45                                                                                                       |
| 2.5. Clinical safety                                                                                                    | .................................................................................................... 46  |
| 2.5.1. Discussion on clinical safety..............................................................................      | 52                                                                                                       |
| 2.5.2. Conclusions on clinical safety ............................................................................      | 55                                                                                                       |
| 2.6. Risk Management Plan........................................................................................       | 55                                                                                                       |
| 2.7. Pharmacovigilance                                                                                                  | ............................................................................................. 57         |
| 2.8. Product information............................................................................................    | 57                                                                                                       |
| 2.8.1. User consultation                                                                                                | ............................................................................................ 57          |
| 2.8.2. Additional monitoring.......................................................................................     | 57                                                                                                       |
| 3. Benefit-Risk Balance.............................................................................                    | 58                                                                                                       |
| 3.1. Therapeutic Context                                                                                                | 58                                                                                                       |
| ........................................................................................... 3.1.1. Disease or condition | ........................................................................................ 58              |
| 3.1.2. Available therapies and unmet medical                                                                            | need....................................................... 58                                           |
| 3.1.3. Main clinical studies.........................................................................................   | 59                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3.2. Favourable effects.............................................................................................. 59    |
|-----------------------------------------------------------------------------------------------------------------------------|
| 3.3. Uncertainties and limitations about favourable effects............................................. 60                 |
| 3.4. Unfavourable effects........................................................................................... 60     |
| 3.5. Uncertainties and limitations about unfavourable effects ......................................... 60                  |
| 3.6. Effects Table...................................................................................................... 61 |
| 3.7. Benefit-risk assessment and discussion................................................................. 61             |
| 3.7.1. Importance of favourable and unfavourable effects.............................................. 61                   |
| 3.7.2. Balance of benefits and risks ............................................................................ 61        |
| 3.8. Conclusions....................................................................................................... 61  |
| 4. Recommendations................................................................................. 61                      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA      | anti-drug antibody                                                                                           |
|----------|--------------------------------------------------------------------------------------------------------------|
| ADCC     | Antibody-Dependent Cell-Mediated Cytotoxicity                                                                |
| AE       | adverse event                                                                                                |
| AESI     | adverse event of special interest                                                                            |
| AI       | AutoInjector                                                                                                 |
| AUC      | area under the concentration-time curve                                                                      |
| AUC      | Analytical ultracentrifugation                                                                               |
| AUC(0-t) | area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration |
| AUC(0-¥) | area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time              |
| BDS      | bulk drug substance                                                                                          |
| BET      | Bacterial Endotoxins Test                                                                                    |
| BLA      | Biologics License Application                                                                                |
| BSE      | Bovine spongiform encephalopathy                                                                             |
| CCI      | Container closure integrity                                                                                  |
| CD       | Circular Dichroism                                                                                           |
| CDR      | Complementarity Determining Region                                                                           |
| CE       | Conformité Européene                                                                                         |
| CEX      | Cation Exchange Chromatography                                                                               |
| CFU      | Colony Forming Unit                                                                                          |
| CGE      | Capillary Electrophoresis                                                                                    |
| CHMP     | Committee for Medicinal Products for Human Use                                                               |
| CHO      | Chinese Hamster Ovary                                                                                        |
| CI       | confidence interval                                                                                          |
| cIEF     | Capillary Isoelectric Focusing                                                                               |
| Cmax     | maximum observed plasma concentration                                                                        |
| CMC      | chemistry, manufacturing, and controls                                                                       |
| COPD     | chronic obstructive pulmonary disease                                                                        |
| CPP      | Critical Process Parameter                                                                                   |

<div style=\"page-break-after: always\"></div>

| CPSR     | clinical pharmacology study report            |
|----------|-----------------------------------------------|
| CQA      | Critical Quality Attributes                   |
| CSR      | clinical study report                         |
| Ctrough  | trough concentration                          |
| CVT      | cardiac, vascular, and thromboembolic         |
| Da       | Dalton                                        |
| DP       | Drug Product                                  |
| DS       | Drug Substance                                |
| DSC      | Differential scanning calorimetry             |
| ECG      | electrocardiogram                             |
| eCRF     | electronic case report form                   |
| EDTA     | ethylenediaminetetraacetic acid               |
| EGPA     | eosinophilic granulomatosis with polyangiitis |
| EMA/EMEA | European Medicines Agency                     |
| ESI-MS   | Electro Spray Ionization Mass Spectra         |
| EU       | European Union                                |
| EU       | Endotoxin Units                               |
| EU-PSUR  | European Union Periodic Safety Update Report  |
| FAAN     | Food Allergy and Anaphylaxis Network          |
| Fab      | Fragment Antigen-binding                      |
| FcRn     | Neonatal FC receptor                          |
| FDA      | Food and Drug Administration                  |
| FTIR     | Fourier transform infrared                    |
| Fuc      | Fucose                                        |
| GCP      | Good Clinical Practice                        |
| GMP      | Good Manufacturing Practices                  |
| GSK      | GlaxoSmithKline                               |
| HC       | Heavy Chain                                   |
| HCP      | healthcare professional                       |
| HCP      | Host Cell Protein                             |
| HES      | hypereosinophilic syndrome                    |

<div style=\"page-break-after: always\"></div>

| HF     | Human Factors                                |
|--------|----------------------------------------------|
| HPLC   | High performance liquid chromatography       |
| IFU    | Instructions for Use                         |
| IgG    | Immunoglobulin                               |
| IgG1   | immunoglobulin G1                            |
| IL-5   | interleukin-5                                |
| IND    | Investigational New Drug                     |
| IPC    | In Process Control                           |
| ISS    | integrated summary of safety                 |
| JNDA   | Japanese New Drug Application                |
| KD     | Dissociation constant                        |
| Kg     | kilogram(s)                                  |
| L      | liter(s)                                     |
| LC     | Light Chain                                  |
| LER    | Low endotoxin recovery                       |
| LOD    | Limit of Detection                           |
| LOQ    | Limit of Quantitation                        |
| LSM    | Large scale manufacturing                    |
| MAA    | Marketing Authorization Application          |
| mAb    | monoclonal antibody                          |
| MALDI  | Matrix-Assisted Laser Desorption/Ionization- |
| MCB    | Master Cell Bank                             |
| MDS    | Mepolizumab drug dubstance                   |
| MedDRA | Medical Dictionary for Regulatory Activities |
| Mg     | milligram(s)                                 |
| mL     | millilitre(s)                                |
| msec   | millisecond                                  |
| MuLV   | Murine Leukemia Virus                        |
| MVD    | Maximum valid dilution                       |
| MVM    | Minute Virus of Mice                         |
| MWCC   | Molecular weight cut off                     |

<div style=\"page-break-after: always\"></div>

| NA or N/A   | Not Applicable                                            |
|-------------|-----------------------------------------------------------|
| NGHC        | Non glycosylated heavy chain                              |
| NIAID       | National Institute of Allergy and Infectious Disease      |
| NLT         | Not Less Than                                             |
| NMR         | Nuclear magnetic resonance                                |
| NMT         | Not More Than                                             |
| NVR         | Non volatile residue                                      |
| OOS         | Out of specification                                      |
| PAI         | pre-approval inspection                                   |
| PBRER       | Period Benefit Risk Evaluation Report                     |
| PCI         | potential clinical importance                             |
| PD          | pharmacodynamic(s)                                        |
| PDE         | Permitted daily exposure                                  |
| PFS         | Prefilled Syringe                                         |
| Ph.Eur.     | European Pharmacopoeia                                    |
| PK          | pharmacokinetic(s)                                        |
| PMDA        | Pharmaceutical and Medical Devices Agency                 |
| PPV         | Porcine Parvovirus                                        |
| PREA        | Pediatric Research Equity Act                             |
| PS80        | Polysorbate 80                                            |
| PSP         | Pediatric Study Plan                                      |
| qPCR        | Quantitative Polymerase Chain Reaction                    |
| QTc QT      | interval corrected for heart rate                         |
| QTOF        | Quadrupole-Time-of-Flight                                 |
| S/N         | Signal-to-Noise Ratio                                     |
| SAE         | serious adverse event                                     |
| SC          | subcutaneous                                              |
| SD          | standard deviation                                        |
| SDS-PAGE    | Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis |
| SEC         | Size Exclusion Chromatography                             |
| SEC-MALLS   | SEC- Multi-Angle Laser Light Scattering                   |

<div style=\"page-break-after: always\"></div>

| SH     | Sulfhydryl group                                                  |
|--------|-------------------------------------------------------------------|
| SMQ    | Standardised Medical Dictionary for Regulatory Activities Queries |
| SOC    | System Organ Class                                                |
| SPR    | Surface Plasmon Resonance                                         |
| SSD    | Syringe safety device                                             |
| SV-AUC | Sedimentation velocity- Analytical ultracentrifugation            |
| TAMC   | Total Aerobic Microbial Count                                     |
| TEM    | Transmission Electron Microscopy                                  |
| TOCS   | Time out of cold storage                                          |
| TSE    | Transmissible Spongiform Encephalopathy                           |
| TYMC   | Total Yeast Microbial Count                                       |
| US     | United States                                                     |
| USP    | United States Pharmacopeia                                        |
| UV     | Ultraviolet                                                       |
| WCB    | Working Cell Bank                                                 |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

GlaxoSmithKline Trading Services Limited submitted on 14 September 2018 an extension of the marketing authorisation as follows:

Extension application to introduce a new pharmaceutical form, solution for injection (in pre-filled syringe or in pre-filled pen).

The Marketing Authorisation Holder (MAH) applied for the following indication for the new pharmaceutical form:

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older (see section 5.1).

## The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008,  (2) point(s)  (d) - Extensions of marketing authorisations

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0239/2017 covering the application on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0239/2017 covering the application was completed.

In addition, the PIP P/0239/2017 eligible for the reward was completed.

The PDCO issued an opinion on compliance for the PIP P/0239/2017 eligible for the reward.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did seek Scientific advice at the CHMP. The scientific advice specific to the development of liquid formulations was provided by EMA/CHMP document references EMA/CHMP/SAWP/271080/2016.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Peter Kiely

Co-Rapporteur:  N/A

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                             | 14 September 2018   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| The procedure started on                                                                                                                                                               | 04 October 2018     |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                         | 20 December 2018    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                    | 03 January 2019     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 17 January 2019     |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                      | 31 January 2019     |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                          | 27 March 2019       |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                | 26 April 2019       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 16 May 2019         |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                       | 23 May 2019         |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Nucala on | 29 May 2019         |

## 2. Scientific discussion

## 2.1. Problem statement

Mepolizumab is already approved as a lyophilised powder in a vial.

This line extension is to introduce a liquid form of mepolizumab drug product in a pre-filled syringe or pre-filled pen/autoinjector. The currently marketed drug product is supplied as a 100 mg single-dose vial containing a sterile, preservative-free, lyophilized powder for reconstitution and subcutaneous injection. The MAH submitted this application to obtain marketing approval for a new drug form (mepolizumab injection, liquid drug product) of mepolizumab in the same and future indications currently registered for the Nucala lyophilised drug product (mepolizumab for injection).

<div style=\"page-break-after: always\"></div>

## 2.1.1. Disease or condition

Asthma is a chronic inflammatory disease of the airways characterized by airway hyper-responsiveness, acute and chronic bronchoconstriction, airway oedema, and mucus plugging. The inflammatory component of asthma involves many cell types, including mast cells, eosinophils, T-lymphocytes, neutrophils, and epithelial cells and their biological products.

The poor response of some patients with asthma to the standard regimen of controller and reliever therapies may  reflect  the  number  of  cellular  and  molecular  mechanisms  operative  in  asthma.  Recent  therapeutic approaches in asthma have been focused on trying to control the Type 2/ T-helper cell-2 (Th2) response. Up-regulation  of  the  Th2  cell-derived  cytokines  interleukin-4  (IL-4)  and  interleukin-13  (IL-13)  has  been implicated as an important inflammatory component of asthma disease progression.

## 2.1.2. Epidemiology

Asthma is a chronic airway disease affecting approximately 334 million people worldwide and is responsible for approximately 250,000 premature deaths each year.

Asthma prevalence varies by geographical region. Accurate assessment of the prevalence of asthma has been hindered  by  varying  definitions  of  asthma  and  methods  of  data  collection,  each  combining  to  make  data comparison across studies difficult.

Risk factors include sex (gender influence varies with age), airway hyper reactivity, atopy, allergens, infections, tobacco smoke, obesity, and perinatal factors.

Asthma is common in adolescents but is frequently undiagnosed because of under-reporting of symptoms.

## 2.1.3. Biologic features

The disease is characterized by airway inflammation with oedema, cellular infiltration and mucus plugging, bronchial smooth muscle hypertrophy which results in variable airway obstruction and bronchial hyper-responsiveness.

## 2.1.4. Clinical presentation, diagnosis

There  is  no  single  diagnostic  test  for  asthma,  the  diagnosis  is  a  clinical  one.  The  absence  of  consistent gold-standard  diagnostic  criteria  means  that  it  is  not  possible  to  make  unequivocal  evidence-based recommendations on how to make a diagnosis of asthma. The diagnosis of asthma in children and adults is based on the recognition of a characteristic pattern of respiratory symptoms, signs and test results and the absence of any alternative explanation for these.

Typical symptoms of asthma include periodic wheezing, chest tightness, shortness of breath, and cough, all of which worsen at night. Patients with asthma experience exacerbations of these symptoms which acutely worsen in response to various triggers such as allergens, microbes, and pollutants, resulting in significant reductions in expiratory flow as measured by forced expiratory volume in 1second (FEV).

Symptoms and signs of asthma in adolescents are no different from those of other age groups.

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

The goals of chronic asthma management may be divided into two domains: reduction in impairment and reduction of risk.

Complete control of asthma is defined as (British Thoracic Society/SIGN guideline):

- no daytime symptoms
- no night-time awakening due to asthma
- no need for rescue medication
- no asthma attacks
- no limitations on activity including exercise
- normal lung function (in practical terms FEV1 and/or PEF&gt;80% predicted or best)
- minimal side effects from medication.

In clinical practice patients may have different goals and may wish to balance the aims of asthma management against the potential side effects or inconvenience of taking medication necessary to achieve perfect control.

Effective  asthma  management  requires  a  proactive,  preventive  approach,  similar  to  the  treatment  of hypertension or diabetes. Routine follow-up visits for patients with active asthma are recommended, at a frequency of every one to six months, depending upon the severity of asthma. These visits should be used to assess multiple aspects of the patient's asthma and to discuss steps that patients can take to intervene early in asthma exacerbations (an asthma \"action plan\"). The aspects of the patient's asthma that should be assessed at each  visit  include  the  following:  signs  and  symptoms,  pulmonary  function,  quality  of  life,  exacerbations, adherence with treatment, medication side effects, and patient satisfaction with care.

Pharmacologic treatment is the mainstay of management in most patients with asthma. The stepwise approach to pharmacotherapy is based on increasing medications until asthma is controlled, and decreasing medications when possible to minimize side effects. Adjustment of the patient's management should be considered at every visit.

The first step in determining appropriate therapy for patients who are not already on a controller medication is classifying the severity of the patient's asthma. For patients already taking one or more controller medications, treatment options are guided by an assessment of asthma control rather than asthma severity.

Specific evidence about the pharmacological management of adolescents with asthma is limited and is usually extrapolated from paediatric and adult studies.

Decreasing  therapy  once  asthma  is  controlled  is  recommended,  but  often  not  implemented  leaving  some patients over-treated.

## About the product

Mepolizumab (SB-240563) is a humanised monoclonal antibody (IgG1, kappa) directed against the human cytokine interleukin-5 (hIL-5), the major cytokine responsible for the growth and differentiation, recruitment, activation and survival, of eosinophils. Mepolizumab binds to human IL-5, preventing IL-5 from binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface and thus inhibiting signalling.

<div style=\"page-break-after: always\"></div>

Neutralisation of IL-5 leads to a reduction in the production rate and survival of eosinophils which is expected to provide therapeutic benefit in hypereosinophilic conditions.

NUCALA (mepolizumab) 100 mg powder for solution for injection was approved on 2nd December 2015 for use as add-on treatment for severe refractory eosinophilic asthma in adult patients.

The  currently  marketed  drug  product  is  supplied  as  a  100  mg  single-dose  vial  containing  a  sterile, preservative-free, lyophilized powder for reconstitution and subcutaneous injection. The MAH submitted this application to obtain marketing approval for a new drug form (mepolizumab injection, liquid drug product) of mepolizumab in the same and future indications currently registered for the Nucala lyophilised drug product (mepolizumab for injection).

The  mepolizumab  liquid  clinical  development  program  consisted  of  three  clinical  studies  designed  to demonstrate:

- Comparable pharmacokinetic systemic exposure between the liquid drug product and the approved lyophilized drug product (Study 204958)
- Real-world usability of the safety syringe and autoinjector devices, along with the IFU, to allow for patient self-administration or administration by a caregiver (Studies 205667 and 204959)
- Comparable safety profile between the liquid drug product and the approved lyophilized drug product (Studies 204958, 205667, and 204959)

In addition Mepolizumab is under development for the treatment of patients with chronic obstructive pulmonary disease (COPD), Eosinophilic Granulomatosis with Polyangiitis (EGPA; also known as Churg-Strauss Syndrome), and hypereosinophilic syndrome (HES). Additional development programs are under consideration based on the mechanism of action of mepolizumab and its effects on eosinophils.

## Type of Application and aspects on development

This is a Centralised Marketing Authorisation Application (MAA) under Article 8(3) of Directive 2001/83/EC for NUCALA® 100 mg powder for solution for injection. The product is eligible for submission of an MAA under Article 3(1) - Indent 1 - Biotech medicinal product of Regulation (EC) No. 726/2004.

GlaxoSmithKline  (GSK)  submitted  this  application  to  obtain  marketing  approval  for  a  new  drug  form (mepolizumab injection, liquid drug product) of mepolizumab in the same and future indications currently registered for the Nucala lyophilised drug product (mepolizumab for injection).

## PRIME

N/A

## 2.2. Quality aspects

## 2.2.1. Introduction

Mepolizumab is currently approved as a 100 mg lyophilised powder for solution for injection in a vial. This line extension seeks to introduce a liquid formulation:

<div style=\"page-break-after: always\"></div>

- 1 mL solution containing 100 mg mepolizumab in a Type 1 glass syringe with a fixed needle and passive safety needle guard (also referred to as safety syringe);

- 1 mL solution containing 100 mg mepolizumab in a Type 1 glass syringe with a fixed needle in a pre-filled pen (also referred to as auto-injector).

The liquid formulation will be marketed as one pre-filled syringe (PFS) or one pre-filled pen (PFP) and multipacks comprising 3 (3 packs of 1) PFS or PFP.

Mepolizumab is formulated with sucrose, sodium phosphate dibasic heptahydrate, citric acid monohydrate, polysorbate 80, EDTA disodium dihydrate and water for injections.

The manufacture of active substance for the liquid formulation duplicates the same process steps used for the previously authorised lyophilised formulation, from vial thaw and cell culture through harvest, purification and virus clearance (Stages 1 through 10). At the Tangential Flow Ultrafiltration step (Stage 11), the processes diverge to accommodate buffer exchange into separate formulations.

A  substantial  amount  of  active  substance  CMC  information  is  therefore  harmonised  for  the  manufacturing processes for the lyophilised and liquid formulations due to their shared manufacturing steps. Where information supportive of the liquid formulation was previously provided in the application for the lyophilised product, the information is included in this application for the liquid product by cross-reference to the approved application. To assist with the cross-referencing strategy, a nomenclature has been developed to identify the processes at each facility:

- MDS2 is the historical code for the approved active substance process for the lyophilised formulation at GSK, Conshohocken.
- MDS2\\_LYO\\_RKV refers to the process for the lyophilised formulation at HGS, Rockville. This process was recently introduced by a Type 1B variation implementing a previously approved post approval change management protocol.
- MDS2\\_LIQ\\_RKV refers to the active substance process for the liquid formulation at HGS, Rockville

## 2.2.2. Active Substance

## General Information

Mepolizumab  is  a  recombinant  humanised  monoclonal  antibody  specific  for  human  IL-5.  The  heavy  chain contains 449 amino acids with an estimated molecular mass of approximately 49 kDa. The light chain contains 220 amino acids with an estimated molecular mass of approximately 24 kDa.

## Manufacture, process controls and characterisation

## Description of manufacturing process and process controls

Mepolizumab is produced in CHO cells using a manufacturing process at the Human Genome Sciences, Inc, Large  Scale  Manufacturing  (LSM)  facility.  The  upstream  manufacturing  process  includes  vial  thaw,  seed expansion, growth of cells and harvest by centrifugation and depth filtration. Downstream processing includes a series of chromatography, ultrafiltration and viral inactivation and filtration steps.

The manufacturing process registered with this line extension is designated as MDS2 LIQ RKV (mepolizumab active substance process 2, liquid, Rockville). The Rockville active substance manufacturing process for the

<div style=\"page-break-after: always\"></div>

currently approved lyophilised finished product is designated MDS2 LYO RKV. MDS2 LIQ RKV is primarily the same as MDS2 LYO RKV, with only minor changes to the purification processes. Minor changes have been made to the registered process parameters.

## Control of materials

The cell  banks  and  most of  the  raw  materials  are  identical  to  those  used  in  manufacture  of  the  currently approved active substance. Details of the raw materials used for the revised Stages 11 and 12 are provided in the dossier along with reference to the relevant pharmacopoeias.

## Control of critical steps and intermediates

Critical  process  parameters (CPPs), acceptable ranges, and associated critical quality attributes (CQAs) for stages  11  and  12  of  the  purification  process  are  presented  in  the  dossier.  The  controls  include  tests  for concentration, bioburden, endotoxin, container closure torque and filter integrity test. The proposed controls are acceptable.

## Process validation

Stages 1-10 have been validated as part of the currently approved process. Validation data is presented from process performance qualification (PPQ) batches for Stages 11 and 12 and includes relevant data from process parameters, CPPs, and in-process controls (IPCs). The results from all PPQ batches were within the relevant acceptance criteria for each control parameter. Impurity clearance data show sufficient clearance of relevant impurities. The data provided demonstrate that Stages 11 and 12 for the MDS2 LIQ RKV process have been successfully validated. A verification protocol has been provided. Hold times are registered throughout the manufacturing process and have been supported by relevant process validation data.

## Manufacturing process development

A comparability study was presented to justify that the MDS2 LIQ RKV process can be considered comparable to the MDS2 / MDS2 LYO KRV process. The comparability studies included in-process data from MDS2 batches, MDS2 LIQ RKV batches and MDS2 LYO RKV batches. During the assessment of the  Type 1B variation to introduce process MDS2 LYO RKV, it was concluded that MDS2 LYO RKV and MDS2 are comparable.  Overall, considering the totality of the comparability data provided in this line extension application, comparability of Stages 1-10 is considered demonstrated.

Process  data  from  Stages  11  and  12  along  with  impurity  clearance  data  support  the  comparability  claim. Comparability was also demonstrated using side-by-side testing of batches of MDS2 and batches of MDS2 LIQ RKV. The data from these tests support the claim of comparability. A comparison of batch release also supported the comparability claim.

The  control  strategy  is  essentially  the  same  as  for  the  approved  active  substance.  Differences  have  been supported by small-scale studies.

## Characterisation

The active substance has previously been characterised in the approved marketing authorisation. Process-related  impurity  clearance  data  has  been  provided  from  MDS2  LIQ  RKV  batches  and  shows  an acceptable level of clearance, which is comparable to the approved active substance.

<div style=\"page-break-after: always\"></div>

## Specification,  analytical  procedures,  reference  standards,  batch  analysis,  and container closure

## Specifications

The  proposed  specifications  include  control  of  identity,  purity,  potency  and  other  general  tests.  They  are generally consistent with those seen for monoclonal antibodies; they are in accordance with ICH Q6B and are accepted. The majority of acceptance criteria are identical to those approved for the MDS2 LYO RKV active substance. The limit for host cell proteins (HCP) is wider than the available batch data; however as part of the ongoing process verification HCP levels in the bulk active substance are monitored to an interim control limit.

## Analytical procedures

Analytical methods which are common to the previously authorised Nucala lyophilised powder formulation are cross-referenced to that dossier. This approach is acceptable as it is confirmed that the methods are identical for both products. Pharmacopoeial methods contain reference to their specific monograph which is acceptable, while  non-pharmacopoeial  methods  are  described  in  the  dossier.  In  general,  the  level  of  description  is acceptable. Overall, the applicant has provided detailed validation reports for new methods and supplementary validation reports for methods previously used for lyophilised active substance. All analytical procedures were validated in accordance with ICH Q2.

## Batch analysis

The applicant has provided batch data for six PPQ batches manufactured according to the proposed commercial process as well as four clinical batches. Results are comparable between batches and meet all specification limits.

## Reference standards

The  approach  to  reference  standards  has  not  changed  from  the  approved  dossier.  The  current  reference standards were assessed during the initial marketing authorisation and continue to be acceptable.

## Container closure system

The primary container closure system was assessed during the initial marketing authorisation and is acceptable.

## Stability

The real-time stability data generated for MDS2 LIQ RKV active substance indicate that the active substance is physically,  chemically  and  biologically  stable  when  stored  at  the  recommended  storage  conditions.  A comprehensive stability protocol has been provided, which tests the main quality attributes at all time-points. Stability reports demonstrate that all quality attributes remained within specification during shelf life. In addition accelerated studies support the stability of the active substance. Photo-stability studies indicate that the active substance is sensitive to degradation upon exposure to light, and therefore should be stored protected from light.

In accordance with EU GMP guidelines (6.32 of Vol. 4 Part I of the Rules Governing Medicinal products in the European Union), any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical Development

The product is presented as a single-use, sterile liquid finished product in a clear glass pre-filled syringe (PFS) intended to deliver 100 mg of mepolizumab for subcutaneous use. It is referred to as MDP3 to differentiate it from the currently approved MDP2 finished product. The primary container and closure consists of a 1 mL long Type 1 glass siliconised barrel with a staked 29G thin wall x 12.7 mm stainless steel needle with a thermoplastic elastomer needle shield covered by rigid plastic shield sealed with a fluororesin coated bromobutyl rubber plunger stopper. The PFS is assembled into either an auto-injector or a safety syringe device. A minimum fill volume of 1.01 mL is provided in the PFS to ensure the required 1.0 mL volume is delivered. The finished product composition includes 100 mg of active substance, sucrose, sodium phosphate dibasic heptahydrate, citric acid monohydrate, polysorbate 80 and EDTA disodium dihydrate.

Sufficient details of the formulation development have been provided. Several formulations were tested which included different buffers as well as different concentrations of sucrose and polysorbate 80. The differences between the liquid and currently registered lyophilised presentation include a lower amount of sucrose, sodium phosphate dibasic heptahydrate and polysorbate 80, and the addition of citric acid monohydrate and EDTA.

Small  scale  process  characterisation  studies  were  carried  out  to  identify  the  CPPs  and  define  the  proven acceptable ranged (PARs). A mixing study was performed at worst case conditions and confirmed that the shear stress does not negatively impact on quality. A filtration study showed no impact on quality. Sufficient data on compatibility has been presented.

The CQAs for the finished product have been listed and were defined based on regulatory requirements and risk assessment. Further details of this risk assessment have been requested. The panel of CQAs cover all relevant aspects of purity, potency and safety.

Comparability studies have been provided to support the comparability of MDP2 and MDP3 finished product. Batches of MDP2 were compared to Batches of MDP3. In addition, a comparison of MDP3 batch data to the historical range of MDP2 batches supported the comparability claim. Extensive forced degradation studies were also carried out which supported comparability.

The primary container closure is a PFS, which is assembled into an auto-injector or safety syringe. Details of design verification and design validation studies have been provided. The technical dossier was provided in 3.2.R. Details of functional performance testing have been provided and include cap removal force, injection actuation force, needle extension, delivered volume, and needle safe distance. In addition, the auto-injector was tested for injection time, audible click, and needle cover over-ride; and the safety syringe was tested for needle guard actuation force, needle guard over-ride force, and needle guard lockout. The testing is in accordance with relevant ISOs 11608 and 11404. Biocompatibility testing has been performed in accordance with ISO 10993-1. Formative and summative human factors studies and real-world use studies have also been performed. The device performance was also evaluated during the PK trial. Overall, the level of detail provided for the PFS, auto-injector and safety syringe is considered acceptable. Extractables and leachables have been sufficiently addressed and are concluded to pose no risk.

## Container closure

The primary container closure system is a PFS, which is assembled into an auto-injector or a safety syringe device. The syringe glass conforms to Ph. Eur. requirements for glass and the proposed specifications are acceptable. They cover relevant tests for visual defects, quality of material, microbial testing and performance

<div style=\"page-break-after: always\"></div>

testing. A specification for silicone is included for the PFS. It has been confirmed that the silicone oil used in the syringes is in conformance with Ph. Eur. 3.1.8 Silicone oil used as a lubricant. The rubber stoppers conform to Ph. Eur. 3.2.9 and the specifications cover visual defects, identity, sterility and dimensional requirements and are acceptable. The names of the PFS and rubber stopper manufacturers have been supplied including the address of the sites responsible for sterilisation. The syringes are sterilised by the supplier using ethylene oxide, and a specification for residual ethylene oxide is included.

Sufficient details and acceptable specifications have been provided for the safety syringe. The auto-injector is manufactured by Ypsomed and is a single-use disposable device, which is not exposed to the finished product. The specifications include visual tests performed by the MAH and functional tests performed by Ypsomed. Relevant functional tests are registered in the specifications (Table 4). A technical dossier for the auto-injector is provided which includes details of conformance with the General Safety and Performance Requirements of the Medical Device Directive. Human factors study reports are also provided. Overall, the level of detail registered for safety syringe and auto-injector is considered acceptable.

## Manufacture of the product and process controls

## Manufacture

The manufacturing process is standard for a monoclonal antibody finished product and has been sufficiently well described in the dossier. Frozen active substance is thawed, pooled and diluted to the target concentration. Formulation buffer and bulk active substance are mixed and then filtered into a holding bag, followed by sterile filtration and filling into PFSs. The PFSs are assembled into an auto-injector or safety syringe.

## Process controls

IPCs are listed throughout the manufacturing. The level of control is considered appropriate for this type of manufacturing process.

## Process validation

Data is provided for five PPQ batches. For manufacture of the formulation buffer and dilution/mixing of the bulk active substance, two samples were taken. For the filling process, six samples were taken. The acceptance criteria for the PPQ campaign were based on the finished product release specifications.  Data are provided on relevant CQAs, CPPs and IPCs throughout the manufacturing process. The assembly into auto-injector or safety syringe was successfully validated and included a sufficient number of functional performance tests. Shipping validation data has also been provided and is acceptable.

Sterile filtration has been sufficiently validated. A microbial retention study was carried out at the maximum flow rate.  Media  fills  have  been  performed  under  worst-case  conditions  and  successfully  passed.  Routine environmental monitoring is also performed. Details of the filter extractable study were provided and the levels identified were below the reporting threshold of daily patient exposure.

## Product specification, analytical procedures, batch analysis

## Specifications

The panel of tests included in the finished product specifications are in accordance with ICH Q6B and cover the relevant  aspects  of  identity,  purity  and  impurities,  potency  and  other  general  tests.  The  testing  panel  is generally consistent with the approved Nucala marketing authorisation. The proposed specifications for device functionality include tests for delivered volume, needle guard lock-out and container closure integrity. Stability

<div style=\"page-break-after: always\"></div>

studies have confirmed acceptable break-loose force and extrusion force over the shelf life of the PFS. The applicant has justified the proposed acceptance criteria for the finished product on the basis that they are the same as the approved lyophilised product, are compendial, or are the same as the clinical acceptance criteria.

## Analytical procedures

There are three finished product specific methods; bioassay, container closure integrity and post-use needle guard lock-out. The other analytical procedures are either compendial, or the same as for the active substance. The descriptions and validation of the analytical methods are acceptable.

## Batch analysis

Batch data has been presented from MDP3 clinical and PPQ batches. The finished product batches were all manufactured  from  active  substance  batches.  From  these  active  substance  batches,  PFS  batches  were manufactured. These PFS batches were used to manufacture safety syringe batches and seven auto-injector batches, for which data is provided. All release data were well within specification and demonstrate that the process is capable of producing finished product batches of consistent quality. In addition to the release tests, the functional testing of the MDP3 PFS batches included maximum break loose force, maximum peak extrusion force and maximum average extrusion force. These tests are for information only and have not been included in the proposed commercial release specifications. This is acceptable.

## Reference standard

The reference standard is described in the active substance section.

## Stability

The proposed shelf life of the finished product is 24 months at 2-8 0 C, plus 1 week at room temperature (up to 30°C/35% residual humidity (RH)) is acceptable. The shelf life specifications are the same as for release, apart from SEC and cIEF. The stability data includes batches from the PFS, auto-injector and safety syringe which are the intended commercial container closure system. The data included storage in the horizontal, upright and vertical  positions.  The  real  time  stability  data  show  no  significant  changes  in  quality  parameters.  At  the accelerated storage condition of 30°C/35%RH, the finished product was out of specification after 3 months. Photostability studies have shown that the finished product is sensitive to light and an appropriate warning is included in Section 6.4 of the SmPC. The product must be administered within 8 hours once the pack is opened.

Stability data from functional assays have been submitted to support the functionality of the PFS across the shelf life. Data are provided for maximum break-loose force, maximum peak extrusion force and maximum average extrusion force. To address the functional performance of the auto-injector during storage, stability data was provided for cap removal force, actuation force, needle cover lockout, needle extension, force to overcome lockout, delivery time, and needle safe distance.

Up to 24 months stability data has been provided which covers the claimed shelf life. The storage conditions also include the possibility of storage for 1 week at 30 0 C. Data has been provided where the finished product was stored for 2 weeks at 30°C/35%RH, followed by 12 months' storage at 2-8 0 C. This stability study is ongoing. In accordance with EU GMP guidelines (6.32 of Vol. 4 Part I of the Rules Governing Medicinal products in the European Union), any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

## Adventitious agents

<div style=\"page-break-after: always\"></div>

None  of  the  steps  which  impact  viral  clearance  is  changed  compared  with  the  approved  process  and  no additional possible sources of viral contamination are introduced.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The active substance manufacturing process is identical to the currently approved mepolizumab active substance manufacturing process apart from the final two manufacturing steps. Comparability to the currently approved process has been shown. The finished product includes a new formulation and a new presentation in a PFS or PFP. Comparability to the currently approved finished product has been demonstrated. The manufacturing process is well under control and the batch data are consistent and the finished product manufacturing process has been validated. Sufficient details have been provided regarding the pre-filled syringe and pre-filled pen, which conform to current legislation and guidance.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

In conclusion, based on the review of the quality data provided, CHMP considers that this line extension application is approvable from the quality point of view.

## 2.2.6. Recommendation(s) for future quality development

None.

## 2.3. Non-clinical aspects

No non clinical data have been submitted in this application. This is acceptable by CHMP.

## 2.4. Clinical aspects

## · Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1 TabularListingofAllMepolizumabLiquidClinicalStudies

| Studyldentifier (ldentifierofStudy Report)                     | Study Objective(s)                                                                   | Study Design                                                   | Healthy Subjects or Diagnosis of Patients                      | Treatment Details(Test Product(s); Dosage Regimen; Route; Duration)                                                                                                       | Total No.of Subjects by Group Entered/ Completed                | Study Reporting Status (Type of Report)                        |
|----------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|
| Pharmacokinetic/PharmacodynamicStudies                         | Pharmacokinetic/PharmacodynamicStudies                                               | Pharmacokinetic/PharmacodynamicStudies                         | Pharmacokinetic/PharmacodynamicStudies                         | Pharmacokinetic/PharmacodynamicStudies                                                                                                                                    | Pharmacokinetic/PharmacodynamicStudies                          | Pharmacokinetic/PharmacodynamicStudies                         |
| 204958 (2017N342446_00)                                        | PK/PD Safety and Tolerability Immunogenicity Safety syringe and autoinjector use     | R, OL, PG                                                      | Healthy subjects                                               | Mepolizumab100mg SC liquid drug product, single dose eitherinautoinjector or safety syringe Mepolizumab100 mgSClyophilisedpowder for solution for injection, single dose. | Autoinjector 79/79 Safety syringe 80/80 Lyopilised powder 85/84 | Completed/ Reported (CPSR)                                     |
| EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid                       | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid                                                                                                            | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid  | EfficacyandSafetyStudies:Controlled ClinicalStudiesUsingLiquid |
| 205687 (2018N371779_00)                                        | Safety and Efficacy in the treatment of nasal polyposis                              | R,DB,PC,PG                                                     | Nasal polyposis                                                | Mepolizumab100mgSC liquid drugproduct Q4W for 52 weeks PlaceboSCQ4Wfor52weeks Administered by ahealthcare professional via a prefilled safety syringe                     | 245 (enrolment in progress)                                     | Ongoing                                                        |
| RealWorldUseandSafetyStudies:UncontrolledClinicalStudies       | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies                             | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies       | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies       | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies                                                                                                                  | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies        | RealWorldUseandSafetyStudies:UncontrolledClinicalStudies       |
| 204959 (2017N349209_00)                                        | Autoinjector use PK/PD Asthma exacerbations Safety and Tolerability Immunogenicity   | OL, RWU                                                        | Severe eosinophilic asthma                                     | Mepolizumab100 mgSC liquid drug product Q4Wfor 12 weeksself-administered by the subject (ortheir caregiver) using an autoinjector.                                        | 159/157a                                                        | Completed/ Reported (CSR)                                      |
| 205667 (2017N331753_00)                                        | Safety syringe use PK/PD Asthma exacerbations Safety and Tolerability Immunogenicity | OL, RWU                                                        | Severe eosinophilic asthma                                     | Mepolizumab100mgSCliquid drugproduct Q4Wfor 12 weeksself-administered by the subject (or their caregiver) using a safety syringe.                                         | 56/55                                                           | Completed/ Reported (CSR)                                      |

19 subjects enrolled and received studymedication in both 205667 and 204959. In all cases,subjects first participated and completed Study 205667 before enrolling in Study ? 204959.

Abbreviations: CPSR= Clinical Pharmacology Study Report; CSR=Clinical Study Report; DB = Double-blind; HCP = Healthcare Professional; mg = miligram(s); OL=Open Label; PC = Placebo-controlled; PD = Pharmacodynamic, PG =Parallel Group; PK = Pharmacokinetic; Q4W=once every4 weeks; R= Randomised, RWU = Real-world Use,SC = Subcutaneous(ly).

## 2.4.1. Pharmacokinetics

## · Introduction

The purpose of this application is to obtain marketing approval for mepolizumab liquid drug product, delivered via a prefilled safety syringe or an autoinjector device, in the same and future indications currently registered for Nucala lyophilised drug product.

Three clinical studies of mepolizumab liquid drug product support this application; a pharmacokinetic (PK) comparability study in healthy subjects (Study 204958), and two Real-World Use studies in subjects with severe eosinophilic asthma, one with the autoinjector (Study 204959) and one with the safety syringe (Study 205667).

## · Methods

## Analytical methods

The same bioanalytical methods used in support of the currently approved lyophilised presentation were used in support  of  the  current  submission  to  evaluate  Mepolizumab  plasma  concentrations  and  presence  of Mepolizumab ADA and NAbs. This approach is acceptable.

The applicant has provided data that shows the assay runs used to analyse samples from the clinical studies met pre-defined acceptance criteria. The data from these runs was therefore valid.

For  evaluation  of  ADAs  in  the  current  submission,  the  method  was  transferred  to  a  new  laboratory.  The validation status of the method has been summarised. This has been performed in accordance with current guidelines. The method remains in a valid state.

Updated sample stability data has also been provided.

Pharmacokinetic data analysis

<div style=\"page-break-after: always\"></div>

Mepolizumab  PK  parameters  were  derived  from  the  plasma  concentration-time  data  for  each  subject  by standard non-compartmental methods using Phoenix WinNonlin Version 6.3.

## Statistical methods

In  the  PK  comparability  study  (204958),  the  primary  statistical  analysis  was  to  compare  the  primary  PK parameters [Cmax, AUC(0-t) and AUC(0-∞)] for each test treatment (liquid drug product in autoinjector or safety syringe) with the reference treatment (reconstituted lyophilised drug product from a vial). The primary PK parameters  were  loge  transformed  and  analysed  separately  using  a  fixed  effects  analysis  of  covariance (ANCOVA) model, including  treatment  group,  injection  site  and  baseline  body  weight  as  covariates.  Point estimates and associated two-sided 90% CIs were constructed for the ratio of the geometric mean of each test treatment to the geometric mean of the reference treatment (obtained by back-transforming estimates and 90% CIs for the treatment differences from the statistical model on the loge scale). The sample size for this study was based on the number of subjects needed to demonstrate a 2-sided 90% CI for the ratio of the geometric mean of each test treatment to the geometric mean of the reference treatment, within the guide range of 0.80-1.25, for primary PK parameters.

In the two real-world use studies (204959 and 205667), statistical analyses were descriptive only and no formal sample size calculations were performed.

In all three studies, analyses were performed on all available data and no imputation was performed for missing data.

- Bioequivalence

Study 204958 was an open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug product in a safety syringe or an autoinjector with a reconstituted lyophilised drug product from a vial.

244 healthy subjects received mepolizumab treatment and provided PK samples for analysis. The demographics and baseline characteristics were comparable across treatment arms. The plasma concentration-time profiles following a single SC dose of mepolizumab 100 mg from the lyophilised drug product or from the liquid drug product, delivered by an autoinjector or a safety syringe, were similar (Figure 3).

<div style=\"page-break-after: always\"></div>

Figure 3 Median Plasma Mepolizumab Concentration-Time Plots by Treatment (Linear and Semi-Log) (Study 204958 PK Population)

<!-- image -->

Source Data: Figure 7.4

Note: Lower limit of quantification = 50 ng/mL

The pharmacokinetics of a single mepolizumab 100 mg SC dose, administered as liquid drug product using either autoinjector or safety syringe, was shown to be statistically comparable to the pharmacokinetics of the commercialized  lyophilized  drug  product.  All  90%  CIs  for  the  treatment  ratios  (liquid  drug  product  in autoinjector vs. lyophilized drug product and liquid drug product in safety syringe vs. lyophilized drug product) of mepolizumab Cmax, AUC(0-∞) and AUC(0-t) were contained within the conventional bioequivalence bounds of 0.80, 1.25 (Table 1).

The similarity of secondary PK parameters (tmax, apparent clearance, terminal phase half-life) across the 3 treatment arms provide further support for the comparability of the 2 test treatments and the reference (Table 10).  The  geometric  mean  extrapolated  portion  of  AUC(0-∞)  was  7  to  8%  (range  for  individual  values 0.5-19.9%). PK parameters were consistent with those observed in a previous study conducted in healthy subjects with the lyophilised drug product (Study SB-240563/018).

<div style=\"page-break-after: always\"></div>

Table 1 Adjusted Treatment Ratios between Mepolizumab Liquid Drug Product in a Safety Syringe (test) or an Autoinjector (test) and Mepolizumab Lyophilized Drug Product (reference) for AUC(0-oo), AUC(0-t), and Cmax (Study 204958, PK Population)

|                     | Mepolizumab100mgSC                       | Mepolizumab100mgSC                     |
|---------------------|------------------------------------------|----------------------------------------|
|                     | Liquid in Safety Syringe vs. Lyophilized | Liquid in Autoinjector vs. Lyophilized |
| AUC(0-00) day*μg/mL | 1.02 (90% CI: 0.95, 1.09)                | 1.07 (90% CI: 1.00, 1.13)              |
| AUC(0-t) day*μg/mL  | 1.04 (90% CI: 0.97, 1.12)                | 1.08 (90% Cl: 1.01, 1.15)              |
| Cmax μg/mL          | 1.06 (90% CI: 0.99, 1.12)                | 1.04 (90% CI: 0.98, 1.11)              |

Source:204958CPSRTable7.13

Note: The estimates of the geometric mean are adjusted for injection site (arm, abdomen, thigh) and baseline weight (loge scale).

<div style=\"page-break-after: always\"></div>

Table 10 Summary of Derived Plasma Mepolizumab PK Parameters Following a Single SC 100 mg Dose by Treatment (Study 204958 PK Population)

|                           | Mepolizumab 100 mg SC      | Mepolizumab 100 mg SC                      | Mepolizumab 100 mg SC                        |
|---------------------------|----------------------------|--------------------------------------------|----------------------------------------------|
| Parameter                 | Lyophilised Vial (N=85)    | Liquid Drug Product In Autoinjector (N=79) | Liquid Drug Product In Safety Syringe (N=80) |
| Primary PK Parameters     |                            |                                            |                                              |
| Cmax (μg/mL)1             | 85 11.57 (10.92, 12.27)    | 79 11.98 (11.27, 12.74)                    | 80 12.07 (11.32, 12.87)                      |
| AUC(0-∞) (day*μg/mL)1     | 84 450.83 (425.67, 477.47) | 79 478.06 (450.47, 507.34)                 | 80 454.11 (423.03, 487.48)                   |
| AUC(0-t) (day*μg/mL)1     | 85 403.84 (377.83, 431.63) | 79 434.49 (411.34, 458.94)                 | 80 415.15 (388.36, 443.78)                   |
| SecondaryPKParameters     |                            |                                            |                                              |
| AUC(0-week4) (day*μg/mL)1 | 84 244.97 (232.64, 257.96) | 79 254.56 (240.97, 268.93)                 | 80 248.81 (233.82, 264.76)                   |
| %AUCex (%)1               | 84 7.67 (6.88, 8.54)       | 79 7.64 (6.55, 8.90)                       | 80 7.20 (6.19, 8.37)                         |
| CL/F (L/day)1,2           | 84 0.222 (0.209, 0.235)    | 79 0.209 (0.197, 0.222)                    | 80 0.220 (0.205, 0.236)                      |
| Vz/F (L)1                 | 84 7.02 (6.69, 7.37)       | 79 6.74 (6.41, 7.08)                       | 80 6.94 (6.53, 7.37)                         |
| t/2 (days)1               | 84 21.95 (21.03, 22.92)    | 79 22.34 (21.21, 23.53)                    | 80 21.83 (20.72, 23.01)                      |
| 入z (/day)1.2              | 84 0.0316 (0.0302, 0.0330) | 79 0.0310 (0.0295, 0.0327)                 | 80 0.0317 (0.0301, 0.0335)                   |
| tmax (days)3              | 85 7.04 (0.9, 14.1)        | 79 7.05 (2.9, 21.0)                        | 80 7.06 (1.9, 14.0)                          |
| tlast (days)3             | 85 83.97 (14.0, 87.0)      | 79 83.98 (81.1, 87.1)                      | 80 83.99 (55.9, 87.9)                        |

SourceData:Table7.5 andTable7.6

1. Number of subjects and geometric mean with 95% Cl presented.

2. Source data unit converted from \"per hour\" to \"per day\" (i.e., x 24).

3. Number of subjects and median (minimum-maximum) presented.

AUC(0-week4) = area under the concentration-time curve from time zero (pre-dose) to Week 4

<div style=\"page-break-after: always\"></div>

Overall, the site of injection (abdomen, thigh, or arm) did not markedly influence mepolizumab PK, irrespective of drug product or device used.

The post-baseline incidence of positive ADA results in this study was low and was similar across the treatment groups (4%, 6% and 4% for the lyophilised drug product, liquid drug product in autoinjector and liquid drug product in safety syringe, respectively). Titres were generally low, with a maximum titre of 320 (in 1 subject in the safety syringe group at Day 29), and decreasing or remaining stable over time. In the 11 subjects with positive post baseline ADA results, there was no evidence of mepolizumab plasma concentrations or blood eosinophil  counts  being  affected  by  the  presence  of  ADAs.  There  was  no  discernible  impact  of  ADAs  on mepolizumab plasma concentrations or blood eosinophils. No subjects tested positive for neutralising antibodies to mepolizumab.

## · Pharmacokinetics in the target population

In subjects with severe eosinophilic asthma, two repeat dose Real-World Use studies of 100 mg SC every 4 weeks for 12 weeks using liquid drug product in autoinjector (Study  204959) or  safety  syringe (Study 205667) were conducted. Both studies were open-label, single arm, repeat dose, multi-centre studies, to evaluate the use of an autoinjector or a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma. In these studies, the PK of mepolizumab was assessed by measuring mepolizumab plasma trough concentrations.

159 subjects and 56 subjects had samples collected for PK assessment in Study 204959 and Study 205667, respectively. In each study, the mean mepolizumab plasma trough concentration increased following each self-administration, and at the End of Study Visit the mean mepolizumab plasma trough concentration was similar to that observed in subjects already receiving mepolizumab at Screening (Figure 3 [204959] and Figure 3 [205667]). Mepolizumab plasma trough concentrations were consistent between studies, and were indicative of correct self-administration by the subjects themselves (or their caregivers) using the autoinjector and safety syringe devices.

<div style=\"page-break-after: always\"></div>

Figure 3 Mepolizumab Plasma Concentration-Time Plots by Baseline Mepolizumab Use (PK Population, Study 204959)

## Semi-LogarithmicScale

<!-- image -->

Source: Figure 8.4.

Note: Data presented as meanISD.

Note: LLQ=50 ng/mL

LLQ = lower limit of quantification.

<div style=\"page-break-after: always\"></div>

Figure 3 Mepolizumab Plasma Concentration-Time Plots by Baseline Mepolizumab Use (PK Population, Study 205667)

## Semi-Logarithmic Scale

<!-- image -->

Source: Figure 8.4.

Note: Data presented as mean±SD.

Note: LLQ=50 ng/mL.

LLQ = lower limit of quantification, mL = millilitre(s), ng = nanogram(s).

When assessed by the site of injection (abdomen, thigh, or arm), the mean mepolizumab concentration-time plots were overall similar across the three sites, irrespective of the device used. However, there is insufficient evidence to conclude no difference in the upper arm site of injection compared to the abdomen or thigh, with only 5 subjects in Study 204959 and 4 subjects in Study 205667 using the upper arm as a site of injection.

Consistent with Study 204958, the post-Baseline incidence of mepolizumab antidrug antibodies in both studies was low and no subjects tested positive for neutralising antibodies to mepolizumab. There was no evidence of mepolizumab plasma trough concentrations and blood eosinophil counts being affected by the presence of ADAs.

## · Conclusion

Overall,  the  PK  of  mepolizumab  was  studied  and  characterised  sufficiently  for  this  application.  In  healthy subjects, the PK of a single mepolizumab 100 mg SC dose, administered as liquid drug product using either autoinjector  or  safety  syringe,  was  shown  to  be  statistically  comparable  to  the  PK  of  the  commercialised lyophilized drug product. In subjects with severe eosinophilic asthma, two repeat dose Real-World Use studies of 100 mg SC mepolizumab every 4 weeks for 12 weeks using liquid drug product in autoinjector or safety syringe,  showed  consistent  mepolizumab  plasma  trough  concentrations.  In  all  studies,  the  post-Baseline

<div style=\"page-break-after: always\"></div>

incidence of mepolizumab antidrug antibodies was low and no subjects tested positive for neutralising antibodies to mepolizumab.

## 2.4.2. Pharmacodynamics

## · Introduction

The pharmacodynamics (PD) of mepolizumab were investigated in three clinical studies. Study 204958 was a comparative PK study conducted in healthy volunteers, which included an exploratory PD analysis. Studies 204959 and 205667 were real-world use studies of mepolizumab in subjects with severe eosinophilic asthma, which included assessments of the PD effect of mepolizumab via an autoinjector (Study 204959) and via a safety syringe (Study 205667).

## · Mechanism of action

Mepolizumab is a humanised monoclonal antibody which interacts with interleukin-5 (IL-5) to inhibit its binding to and signalling via the cell-surface IL-5 receptor complex expressed on eosinophil cells. IL-5 promotes the proliferation of eosinophils, and the antagonistic action of mepolizumab results in reduced blood, sputum, and tissue eosinophils.

## · Primary pharmacology

Mepolizumab produces a reduction of blood eosinophil levels and has shown clinical benefit in the treatment of severe eosinophilic asthma.

Study  204958 was  a  comparative PK study in healthy volunteers. This study included an exploratory PD analysis, to evaluate mepolizumab PD effects on blood eosinophil count following a single 100 mg SC dose of liquid drug product, in safety syringe or autoinjector, in comparison with the reconstituted lyophilised drug product.

In all treatment groups, a single dose of mepolizumab produced a decrease in eosinophil counts up to Day 29, which then started to return towards baseline. The reductions in blood eosinophil counts observed using the liquid drug product in autoinjector or safety syringe were comparable, and comparable with the lyophilized drug product.

Geometric mean ratios to baseline blood eosinophils over time (adjusted for baseline blood eosinophil count [loge scale], injection site [arm, abdomen, thigh] and baseline weight [loge scale]) were similar across the 3 treatment groups with a value of 0.335, 0.344 and 0.311 (a reduction from baseline of 67%, 66% and 69%) at Day 29 for the lyophilised drug product, liquid drug product in autoinjector and liquid drug product in safety syringe, respectively.

In the comparisons of the liquid drug product in autoinjector and the liquid drug product in safety syringe with the lyophilised drug product, the geometric mean ratios of blood eosinophil counts for both comparisons were approximately 1 (range 1.029 to 1.147 for the liquid drug product in autoinjector vs lyophilised drug product comparison  and  0.929  to  1.123  for  the  liquid  drug  product  in  safety  syringe  vs  lyophilised  drug  product comparison). This suggests that both test treatments (liquid drug product in autoinjector or safety syringe) had similar effects on blood eosinophils as the lyophilised drug product.

Studies 204959 and 205667 were real-world use studies of mepolizumab in subjects with severe eosinophilic asthma, which included assessments of the PD effect of mepolizumab. The PD profile of mepolizumab liquid drug

<div style=\"page-break-after: always\"></div>

product in an autoinjector or safety syringe was assessed by measuring blood eosinophils. 158 subjects and 56 subjects had samples collected for PD assessment in studies 204959 and 205667, respectively.

In subjects with severe eosinophilic asthma, 100 mg SC every 4 weeks for 12 weeks using liquid drug product in autoinjector (Study 204959) or safety syringe (Study 205667), resulted in a sustained reduction in blood eosinophil  counts.  The  reductions  in  blood  eosinophil  counts  observed  using  the  liquid  drug  product  in autoinjector or safety syringe were comparable (Figure 4 Study 204959 and Figure 4 Study 205667). Blood eosinophil counts were indicative of correct self-administration by the subjects (or their caregivers) using the autoinjector and safety syringe devices.

Figure 4 Summary of Ratio to Baseline Blood Eosinophils by Visit and Baseline Mepolizumab Use (PD Population, Study 204959)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 Summaryof Ratio toBaselineBlood EosinophilsbyVisitand Baseline Mepolizumab Use (PD Population, Study 205667)

<!-- image -->

Overall, in subjects with severe eosinophilic asthma, the site of injection (abdomen, thigh, or arm) did not appear to influence the effect of mepolizumab on blood eosinophils, irrespective of the device used, although there were too few subjects using the upper arm site in either study to be able to conclude no difference.

## · Conclusion

The PD of mepolizumab was studied and characterised sufficiently for this application. In healthy subjects, a single 100 mg SC dose of mepolizumab produced a decrease in eosinophil counts up to Day 29. The reductions in  blood  eosinophil  counts  observed  using  the  liquid  drug  product  in  autoinjector  or  safety  syringe  were comparable, and comparable with the lyophilized drug product.

In subjects with severe eosinophilic asthma, 100 mg mepolizumab SC every 4 weeks for 12 weeks, using liquid drug product in autoinjector or safety syringe, resulted in a sustained reduction in blood eosinophil counts. The reductions in blood eosinophil counts observed using the liquid drug product in autoinjector or safety syringe were comparable.

## 2.4.3. Discussion on clinical pharmacology

To support the development of the liquid formulation administered via a safety syringe or an autoinjector, three clinical studies were conducted; a PK comparability study in healthy subjects (204958), and two Real-World Use studies in subjects with severe eosinophilic asthma, one with the autoinjector (204958) and one with the safety syringe (205667).

Pharmacokinetics and pharmacodynamics in healthy subjects

<div style=\"page-break-after: always\"></div>

In  the  PK  comparability  study  (Study  204958),  244  healthy  subjects  were  administered  a  single  dose  of mepolizumab 100 mg SC by a health care professional. The primary PK endpoints were Cmax, AUC(0-∞), and AUC(0-t).

The design of this study is considered acceptable. The parallel group design was appropriate given the long half-life  of  mepolizumab  and  the  potential  influence  of  immunogenicity  with  a  cross-over  design.  The demographics and baseline characteristics were well balanced between the 3 treatment arms. The sampling time  points  were  adequate  for  characterisation  of  the  whole  mepolizumab  PK  profile,  including  the  late elimination phase. The collection of samples up to Day 85 ensured that the extrapolated portion of AUC(0-∞) was less than 20% in all subjects.

The results provide evidence for statistical PK comparability between the liquid drug product, in a safety syringe or an autoinjector, and the lyophilised drug product. All 90% CIs of the geometric mean ratios of primary PK parameters were contained well within the predefined equivalence margin (0.80 to 1.25). The similarity of secondary PK parameters (tmax, apparent clearance, terminal phase half-life) across the 3 treatment arms further supports the comparability of the liquid drug product (autoinjector or safety syringe) and the lyophilized drug product.

In the exploratory PD component of this study, the geometric mean ratios of blood eosinophil counts for the comparisons of the liquid drug product in autoinjector and in safety syringe with the lyophilized drug product were approximately unity at the various time-points, with the 95% CIs for the ratios falling within bounds of 0.70, 1.43 (±30%). This suggests that both test treatments (liquid drug product in autoinjector or safety syringe) and lyophilized drug product had similar effects on blood eosinophils, although these wider confidence bounds were not defined or justified in the study protocol.

Overall, the site of injection (abdomen, thigh, or arm) did not appear to markedly influence mepolizumab PK, nor the effect of mepolizumab on blood eosinophils, irrespective of drug product or device used.

A number of other concerns were raised for this study, as follows:

1. At pre-dose, 11 subjects had measurable plasma mepolizumab concentrations, with 2 of these subjects having pre-dose concentrations &gt;5% of their respective Cmax. In line with the EMA bioequivalence guideline,  subjects  with  non-zero  baseline  concentrations  &gt;5%  of  Cmax  should  be  excluded  from bioequivalence calculations. The applicant was asked to justify the non-exclusion of these 2 subjects from the statistical analysis. The applicant was also asked to provide an explanation for subjects having measurable mepolizumab concentrations before receiving the first dose.

In response to this concern, the applicant conducted a sensitivity analysis excluding the 2 subjects with pre-dose concentration &gt;5% of Cmax and the results showed that the exclusion of these 2 subjects had no impact on the interpretation of the study results. The applicant also provided confirmation that the method used for sample analysis was validated for being accurate, precise, selective, sensitive and reproducible. This issue was concluded to be resolved.

2. The applicant reported performing a database unfreeze to allow for the reanalysis of PK samples with measurable concentrations  prior  to  administration  of  mepolizumab  as  well  as  2  unexpectedly  high concentrations (post-dosing), and to investigate a potential swapping of samples. Derivation of PK parameters and statistical analysis had not been completed at that stage. This reanalysis of the PK samples resulted in final PK concentrations for 15 samples in 14 subjects being updated. However, reanalysis of samples did not appear to be addressed in the study protocol. Therefore, in terms of the reanalysed  samples,  the  applicant  was  asked  to:  (i)  identify  and  provide  the  initial  value  of  the reanalysed samples; (ii) provide the reason for reanalysis; (iii) provide the values obtained in the

<div style=\"page-break-after: always\"></div>

reanalysis; (iv) provide the finally accepted value; and (v) provide a justification for the acceptance of this value.

In response to this concern, the applicant identified the samples and provided the rationale for their re-analysis. The initial value of the reanalysed samples, the values obtained in the re-analysis and the final  accepted  values  were  provided.  A  justification  for  the  acceptance  of  the  final  value  was  also provided. Given the low number of samples re-analysed, this was considered acceptable and the issue was concluded to be resolved.

3. The applicant was asked to clarify how data below the lower limit of quantification were handled.

In response to this concern, the applicant provided an adequate clarification of how data below the LLOQ was handled and the matter was concluded to be resolved.

4. Pharmacokinetic data source Table 7.1 (Summary of Plasma Mepolizumab Concentration-Time Data by Treatment)  showed  that  data  were  imputed  at  pre-dose,  2  hours  and  8  hours  post-dose,  and  at follow-up time points. The study report stated that analyses were performed on all available data and that  no  imputation  was  performed  for  missing  data.  The  applicant  was  asked  to  explain  these imputations.

In  response  to  this  concern,  the  applicant  explained  that  the  imputation  relates  to  BLQ  data  and confirmed that there was no imputation of missing data. The matter was concluded to be resolved.

5. The applicant was asked to provide the following (per EMA bioequivalence guideline): (i) individual concentration data and PK parameters listed by drug product; (ii) the number of points on the terminal log-linear phase used to estimate the terminal rate constant for each subject; and (iii) the analysis of covariance tables, including the appropriate statistical tests of all effects in the model.

In response to this concern, the applicant provided individual concentration data and PK parameters listed by drug product. In all subjects, the number of points on the terminal log-linear phase used to estimate the terminal rate constant for each subject was greater than three. The analysis of covariance tables, including the appropriate statistical tests of all effects in the model were provided and discussed. The matter was concluded to be resolved.

## Pharmacokinetics and pharmacodynamics in severe eosinophilic asthma subjects

In subjects with severe eosinophilic asthma, two repeat-dose Real-World Use studies of 100 mg SC every 4 weeks for 12 weeks using liquid drug product in autoinjector (Study 204959) or safety syringe (Study 205667), showed consistent mepolizumab plasma trough concentrations and blood eosinophil counts.

159 subjects and 56 subjects had samples collected for PK and PD assessment in Study 204959 and Study 205667, respectively. In each study, the mean mepolizumab plasma trough concentration increased following each self-administration, and at the End of Study Visit the mean mepolizumab plasma trough concentration was similar to that observed in subjects already receiving mepolizumab at Screening. Mean mepolizumab plasma trough concentrations were comparable in subjects using the liquid product in autoinjector or safety syringe.

Mepolizumab 100 mg SC every 4 weeks for 12 weeks, using liquid drug product in autoinjector or safety syringe, resulted in a sustained reduction in blood eosinophil counts. The reductions observed in blood eosinophil counts using the liquid drug product in autoinjector or safety syringe were comparable.

Plasma trough concentrations and blood eosinophil counts observed in these studies were indicative of correct self-administration by the subjects themselves (or their caregivers) using the autoinjector and safety syringe devices.

<div style=\"page-break-after: always\"></div>

Overall, the site of injection (abdomen, thigh or arm) did not appear to markedly influence mepolizumab PK, nor the effect of mepolizumab on blood eosinophils, irrespective of device used. However, there is insufficient evidence to conclude no difference in the upper arm site of injection compared to the abdomen or thigh, with only 5 subjects in Study 204959 and 4 subjects in Study 205667 using the upper arm as a site of injection. Further discussion to support the recommendation of the 3 injection sites (upper arm, thigh and abdomen as per the proposed SmPC) is requested to be provided.

In  response  to  this  concern,  the  applicant  explained  that  the  principal  data  supporting  the  similarity  of mepolizumab  between  the  three  sites  of  injection  (abdomen,  thigh  and  upper  arm)  comes  from  the  PK comparability study 204958, rather than from studies 204959 and 205667 which were real world use studies where the upper arm was only permitted as an injection site if the injection was administered by a caregiver. In the parallel group study 204958, injection site was randomised 1:1:1 to the abdomen, arm and thigh arm and 80, 80 and 84 subjects received injections, respectively. For each of the three PK parameters (AUC(0-∞ ), AUC(0-t) and Cmax) and three injection sites, the 90% confidence interval for eight out of the nine pairwise comparisons is contained within the 0.8, 1.25 bounds required to demonstrate PK comparability. The single exception; Cmax for arm vs. thigh, has a lower 90% confidence interval bound of 0.78, which is sufficiently close to 0.8 to be unremarkable.

The explanation was considered adequate to support the conclusion of no difference in the upper arm site of injection compared to the abdomen or thigh. The matter was concluded to be resolved.

Impact of immunogenicity on PK and PD of mepolizumab

The post-baseline incidence of mepolizumab ADAs was consistently low across the three clinical studies, and there was no discernible impact of ADAs on mepolizumab plasma concentrations or blood eosinophil counts. No subjects tested positive for neutralising antibodies.

## 2.4.4. Conclusions on clinical pharmacology

Overall, the PK and PD of mepolizumab were studied and characterised sufficiently for this application. The applicant's conclusions are generally supported. In healthy subjects, the PK of a single mepolizumab 100 mg SC dose,  administered  as  liquid  drug  product  using  either  autoinjector  or  safety  syringe,  was  shown  to  be statistically  comparable  to  the  PK  of  the  commercialized  lyophilized  drug  product.  In  subjects  with  severe eosinophilic asthma, two repeat dose Real-World Use studies of 100 mg SC mepolizumab every 4 weeks for 12 weeks using liquid drug product in autoinjector or safety syringe, showed consistent mepolizumab plasma trough concentrations. The reductions in blood eosinophil counts observed using the liquid drug product in autoinjector or safety syringe were comparable, and comparable with the lyophilized drug product.

No major objections were raised with the PK or PD analyses. Some other concerns were raised to which the applicant responded adequately. All of these issues were concluded to be resolved.

## 2.4.5. Clinical efficacy

GlaxoSmithKline  (GSK)  is  submitting  this  application  to  obtain  marketing  approval  for  a  new  drug  form (mepolizumab injection, liquid drug product) of mepolizumab in the same and future indications currently registered for the Nucala lyophilised drug product (mepolizumab for injection).

Only limited efficacy data were provided as part of this application.

<div style=\"page-break-after: always\"></div>

The mepolizumab liquid drug product clinical development programme consisted of 3 studies which support this application: 1 pharmacokinetic (PK) comparability study in healthy volunteers and 2 Real-World-Use (RWU) studies in subjects with severe eosinophilic asthma. All 3 studies assessed the safety profile of the mepolizumab liquid drug product.

2 Real-World-Use (RWU) studies are discussed in the PK, efficacy and safety section of this assessment report.

The pharmacokinetic (PK) comparability study is discussed in the PK and safety section of this assessment report.

In addition the applicant performed Human Factors studies on the instructions for use in the Nucala leaflet. They are discussed in the efficacy section as well.

## 2.4.6. Dose response study

Not applicable.

## 2.4.7. Main study

There are no main studies in this application, only supportive studies described below.

## Supportive studies

## Real-world use studies 204959 and 205667

Two separate open-label, single-arm, multi-dose, multi-center, 12-week studies were conducted to investigate the real-world use of an autoinjector (204959) and a safety syringe (205667) in subjects ≥12 years of age with severe eosinophilic asthma. In study 204959, two autoinjector device labels were used: standard device label + pictogram and standard device label.

The  objective  of  these  studies  was  to  assess  the  correct  real-world  use  of  the  devices  for  the  repeat self-administration (or caregiver administration) of mepolizumab 100 mg SC by determining the proportion of subjects who were successfully able to self-administer a dose. Three doses of mepolizumab were administered: the first and third injections (Week 0 and Week 8) were self-administered under observation in the clinic; the second injection (Week 4) was self-administered at home. Training on the study treatment, device handling and administration techniques, including a review of the instructions for use (IFU), was provided by the investigator or qualified site staff immediately prior to self-administration of the first dose at Week 0. Quantitative and qualitative subject feedback regarding the device use and the IFU were obtained at the end of each study. The primary endpoint for both studies was the proportion of subjects who were successfully able to self-administer their third observed dose at Week 8.

For  each  self-administration  (or  caregiver  administration),  injection  success  was  determined  by  the investigator/site  staff,  by  reviewing  the  steps  required  to  successfully  administer  the  injection  against  a checklist (i.e., Observer Checklist for in-clinic administrations or the At-Home Checklist for injections outside the clinic) alongside findings from  the visual inspection of the device following the injection (in-clinic administrations) or when returned to the site.

At the end of the study, the individual who performed the injections (subject or caregiver) completed a Device Usability/Functionality Questionnaire which captured the individual's perception of the training provided by the investigator/site staff for use of the device, the IFU supplied, and the usability and convenience of the device.

<div style=\"page-break-after: always\"></div>

Exit Interviews were conducted in a subset of subjects at selected sites within 6 weeks following the final visit to qualitatively assess their experience with mepolizumab liquid drug product in an autoinjector (with either device label) or safety syringe. Exit Interviews were conducted over the telephone in a semi-structured format by a trained interviewer and analysed by a third-party provider.

## Results

159 subjects were enrolled in the autoinjector study (104 using the standard device label + pictogram and 55 using the standard device label) and 56 subjects were enrolled in the safety syringe study. The majority of subjects (73% in Study 204959 and 71% in Study 205667) had no prior self-injection experience.

Nearly  all  subjects  (≥98%)  completed  the  studies.  Three  subjects  discontinued  prematurely.  None  of  the withdrawals were considered related to study treatment by the investigator.

## Autoinjector assessment (Study 204959)

## Assessment of injection success

- Autoinjector with Standard Device Label + Pictogram

For  the  primary  endpoint,  all  but  one  subject  (&gt;99%)  successfully  self-administered  the  third  dose  of mepolizumab on the first attempt at Week 8 using the standard device label + pictogram autoinjector (Table 11). The one subject who had an unsuccessful injection made a per-protocol error of selecting an incorrect injection site (upper arm), but received the dose of study treatment.

Over the course of the study, injection success rate was high with 95%  of subjects able to self-administer/caregivers administer all three doses of mepolizumab on the first attempt using the standard device label + pictogram autoinjector. Five subjects (5%) had an unsuccessful injection due to one or more user errors, 3 due to selecting the incorrect injection site per-protocol (upper arm intended for caregiver only), one due to pulling the autoinjector away before the end of the injection on the first dose, and one due to a reported device error (unsubstantiated following root-cause analysis) prior to the second dose. Four of the 5 subjects corrected their errors at subsequent injections; the 5th subject selected the incorrect injection site for the injection of two doses.

<div style=\"page-break-after: always\"></div>

Table 11 Injection Success on First Attempt (Real World Use Study 204959, Autoinjector Standard Device Label + Pictogram, All Subjects)

|                                                       | Mepolizumab Liquid Autoinjector (Standard Device Label +Pictogram) N=104   | Mepolizumab Liquid Autoinjector (Standard Device Label +Pictogram) N=104   | Mepolizumab Liquid Autoinjector (Standard Device Label +Pictogram) N=104   | Mepolizumab Liquid Autoinjector (Standard Device Label +Pictogram) N=104                                                             |
|-------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Visit                                                 | Attempted Injection(s) n                                                   | Successful Injectiona,b n (%) [95% CI]                                     | Unsuccessful Injectionb n (%)                                              | Reason for Failure, n                                                                                                                |
| Week 0,First dose (observed in clinic)                | 104                                                                        | 101 (97) [92, 99]                                                          | 3 (3)                                                                      | Incorrect injection site (upper arm)- 2c Pen pulled away before end of injection, evidence of liquid leaking from injection site- 1d |
| Week 4, Second dose (unobserved at home)              | 103                                                                        | 101 (98) [93, 100]                                                         | 2 (2)                                                                      | Incorrect injection site (upper arm)- 1c                                                                                             |
| Week 4, Second dose (unobserved at home)              | 103                                                                        | 101 (98) [93, 100]                                                         | 2 (2)                                                                      | Other user/reported device error- 1e                                                                                                 |
| Week8,Thirddose Primary endpoint (observed in clinic) | 103                                                                        | 102 (99) [95, 100]                                                         | 1(<1)                                                                      | Incorrect injection site (upper arm)- 1c                                                                                             |
| Weeks 4 and 8                                         | 103                                                                        | 100 (97) [92, 99]                                                          |                                                                            |                                                                                                                                      |
| Weeks 0, 4, and 8                                     | 103                                                                        | 98 (95) [89, 98]                                                           |                                                                            |                                                                                                                                      |

Source: 204959 CSR Table 7.1, Table 7.5, and Listing 16

- a. The denominator was the number of subjects/caregivers attempting an injection at that visit. Where multiple visits were assessed, the denominator was the number of subjects/caregivers attempting an injection at all the applicable visits.
- b. Investigator evaluation
- C. This error was classified as unsuccessful per-protocol. Despite this error, the subject received the dose of study treatment on initial attempt. One subject made this error at Weeks O and 4.
- d. Second attempt at the first dose also resulted in an unsuccessful injection (\"pen was not pushed all the way down third doses were successfully self-administered by the subject on first attempt.
- e. attempt with another autoinjector was successful.
- Autoinjector with Standard Device Label

For  the  primary  endpoint,  all  but  one  subject  (98%)  successfully  self-administered  the  third  dose  of mepolizumab on the first attempt at Week 8 using the standard device label autoinjector (Table 12). The one subject who had an unsuccessful injection made a per protocol error of selecting an incorrect injection site (upper arm), but received the dose of study treatment.

Over the course of the study, injection success rate was high with 89% of subjects able to self-administer (or caregivers  administer)  all  three  doses  of  mepolizumab  (Weeks  0,  4  and  8)  on  the  first  attempt  using  the standard device label autoinjector. Six subjects (11%) had an unsuccessful injection each due to one or more user errors: 4 due to pulling the autoinjector away before the end of the injection (2 on the first dose and 2 on the  second  dose),  one  due  to  a  reported  device  error  on  the  first  dose  (leakage  from  injection  site  when removing the autoinjector), which was unsubstantiated following root-cause analysis, and one due to selecting the  incorrect  injection  site  (upper  arm).  All  subjects  corrected  their  errors  at  subsequent  injections,  as applicable.

<div style=\"page-break-after: always\"></div>

Table 12 Injection on First Attempt (Real-World Use Study 204959, Autoinjector Standard Device Label, All Subjects)

|                                                          | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55            |
|----------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------|
| Visit                                                    | Attempted Injections n                                       | Successful Injectiona n (%) [95% CI]                         | Unsuccessful Injectionb n (%)                                | Reason for Failure, n                                                 |
| Week O, First dose (observed in clinic)                  | 55                                                           | 52 (95) [85, 99]                                             | 3 (5)                                                        | Pen pulled away before end of injection, reported device failure- 1cd |
| Week O, First dose (observed in clinic)                  | 55                                                           | 52 (95) [85, 99]                                             | 3 (5)                                                        | Pen pulled away before end of injection- 1c                           |
| Week 4, Second dose (unobserved at home)                 | 54                                                           | 52 (96) [87, 100]                                            | 2 (4)                                                        | Pen pulled away before end of injection- 1                            |
| Week 4, Second dose (unobserved at home)                 | 54                                                           | 52 (96) [87, 100]                                            | 2 (4)                                                        | Pen pulled away before end of injection, reported device failure- 1d  |
| Week 8, Third dose Primary endpoint (observed in clinic) | 54                                                           | 53 (98) [90, 100]                                            | 1 (2)                                                        | Incorrect injection site (upper arm)- 1f                              |
| Weeks 4 and 8                                            | 54                                                           | 51 (94) [85, 99]                                             |                                                              |                                                                       |
| Weeks 0, 4, and 8                                        | 54                                                           | 48 (89) [77, 96]                                             |                                                              |                                                                       |

Source: 204959 CSR Table 7.2, Table 7.6, and Listing 16

- a. The denominator was the number of subjects/caregivers attempting an injection at that visit. Where multiple visits visits.
- b. Investigator evaluation
- C. Subject made a successful repeat attempt at injection
- d. The investigator/site staff entered explanatory text under the 'device failure' section on the eCRF describing the user error.
- e. Root-cause analysis concluded no device error occurred (204959 CSR Section 15.4).
- f. study treatment on initial attempt.

<div style=\"page-break-after: always\"></div>

Table 12 Injection on First Attempt (Real-World Use Study 204959, Autoinjector Standard Device Label, All Subjects)

|                                                          | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55   | MepolizumabLiquidAutoinjector (Standard Device Label) N=55            |
|----------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------|
| Visit                                                    | Attempted Injections n                                       | Successful Injectiona n (%) [95% CI]                         | Unsuccessful Injectionb n (%)                                | Reason for Failure, n                                                 |
| Week O, First dose (observed in clinic)                  | 55                                                           | 52 (95) [85, 99]                                             | 3 (5)                                                        | Pen pulled away before end of injection, reported device failure- 1cd |
| Week O, First dose (observed in clinic)                  | 55                                                           | 52 (95) [85, 99]                                             | 3 (5)                                                        | Pen pulled away before end of injection- 1c                           |
| Week 4, Second dose (unobserved at home)                 | 54                                                           | 52 (96) [87, 100]                                            | 2 (4)                                                        | Pen pulled away before end of injection- 1                            |
| Week 4, Second dose (unobserved at home)                 | 54                                                           | 52 (96) [87, 100]                                            | 2 (4)                                                        | Pen pulled away before end of injection, reported device failure- 1d  |
| Week 8, Third dose Primary endpoint (observed in clinic) | 54                                                           | 53 (98) [90, 100]                                            | 1 (2)                                                        | Incorrect injection site (upper arm)- 1f                              |
| Weeks 4 and 8                                            | 54                                                           | 51 (94) [85, 99]                                             |                                                              |                                                                       |
| Weeks 0, 4, and 8                                        | 54                                                           | 48 (89) [77, 96]                                             |                                                              |                                                                       |

Source: 204959 CSR Table 7.2, Table 7.6, and Listing 16

- a. The denominator was the number of subjects/caregivers attempting an injection at that visit. Where multiple visits visits.
- b. Investigator evaluation
- C. Subject made a successful repeat attempt at injection
- d. The investigator/site staff entered explanatory text under the 'device failure' section on the eCRF describing the user error.
- e. Root-cause analysis concluded no device error occurred (204959 CSR Section 15.4).
- f. study treatment on initial attempt.

## Device usability and functionality

Responses from the usability/functionality questionnaire revealed an overall positive experience from subjects (or their caregivers) regarding the training provided by the investigator/site staff, clarity of the IFU, and the usability of the standard device label + pictogram autoinjector or the standard device label autoinjector (Table 13).

Subjects/caregivers felt comfortable with the in-clinic training provided on the autoinjector, and only a small percentage of subjects (11% to 12%) requested additional guidance (review of the IFU and/or answering questions related to the IFU) prior to the unobserved, at home injection. Most subjects/caregivers found the IFU steps to be clear and understandable.

<div style=\"page-break-after: always\"></div>

Most subjects/caregivers felt confident using the autoinjector based on the IFU and their ability, and found it easy  and  convenient  to  use.  Nearly  all  of  the  153  subjects  questioned  (99%)  expressed  that  they  would recommend the mepolizumab liquid drug product in an autoinjector to other patients with asthma. Of the subjects  previously  receiving  mepolizumab  administered  by  a  HCP  (n=72),  almost  all  (96%)  expressed  a preference for receiving mepolizumab using an autoinjector at home rather than an injection administered by a HCP.

Table 13 Device Usability and Functionality Questionnaire Summary (RealWorld Use Study 204959, All Subjects)

|                                                                                                           | Number (%) of Subjects Mepolizumab Liquid Autoinjector   | Number (%) of Subjects Mepolizumab Liquid Autoinjector   |
|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Response to Question                                                                                      | Standard device label + pictogram N=104                  | Standarddevicelabel N=55                                 |
| n completing questionnaire                                                                                | 102                                                      | 51                                                       |
| Very or extremely comfortable with in-clinic training provided                                            | 98 (96)                                                  | 45 (88)                                                  |
| Requested additional guidance prior to at-home injection                                                  | 12 (12)                                                  | 6 (11)                                                   |
| IFU steps very or extremely clear and understandable1                                                     | 94 (92) to 98 (96)                                       | 45 (88) to 47 (92)                                       |
| Very or extremely confident using autoinjector on your own based on the IFU                               | 97 (95)                                                  | 46 (90)                                                  |
| At the end of the study, very or extremely confident in ability to use autoinjector correctly on your own | 98 (97)                                                  | 45 (88)                                                  |
| Autoinjector is very or extremely easy to use at home                                                     | 94 (92)                                                  | 44 (86)                                                  |
| Very or extremely convenient to receive mepolizumab using the autoinjector at home                        | 97 (95)                                                  | 47 (92)                                                  |
| Would recommend autoinjector to other patients with asthma                                                | 100 (98)                                                 | 51 (100)                                                 |
| Prefer to use autoinjector at home rather than have administered by HCP2                                  | 45/47 (96)                                               | 24/25 (96)                                               |

- Questions were asked on various individual steps in the IFU

2. Question only asked for subjects receiving mepolizumab at baseline

## Exit interviews

Reponses from the Exit Interviews conducted in a subset of 25 subjects at selected sites who used either the standard device label + pictogram autoinjector (n=11) or the standard device label autoinjector (n=14), were consistent with the positive findings from the device usability/functionality questionnaire. During the interviews, subjects generally expressed that feelings of anxiety or concern associated with autoinjector use decreased after the first administration. All subjects reported that the ease and convenience of self-administering mepolizumab using the autoinjector underpinned their positive impressions and all interviewed subjects saw no problems in incorporating the self-injection using the autoinjector into their lifestyles. Around half (48%) of subjects stated that they felt pain when using the autoinjector, but stated that it was mild and localised to the injection site.

## Reliability

<div style=\"page-break-after: always\"></div>

No  substantiated  device  failures  occurred  with  the  autoinjector  during  the  Real-World  Use  clinical  study. Additionally,  when  100  of  the  returned  autoinjectors  used  by  subjects/caregivers  in  Study  204959  were inspected as a representative sample of used autoinjectors, no undetected malfunctions were found.

## Safety syringe assessment (Study 205667)

## Assessment of injection success

In the Real-World Use study, a 100% injection success rate was reported across all injection endpoints with the safety syringe (Table 9). All subjects/caregivers were reported by the investigator/site staff to have successfully self-administered their first, second, and third dose of mepolizumab liquid drug product using the safety syringe.

Table 9 Proportion of Subjects Successfully Able to Self-Administer Mepolizumab by Visit (Real-World Use Study 205667, Safety Population)

|                                                              | Mepolizumab Liquid Safety Syringe N=56   | Mepolizumab Liquid Safety Syringe N=56   | Mepolizumab Liquid Safety Syringe N=56   |
|--------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                              | Attempted Injection(s)                   | Successful Injections1.2                 | Successful Injections1.2                 |
| Timepoint                                                    | n                                        | n (%)                                    | 95% CI                                   |
| Week 0, First Dose (observed in the clinic)                  | 56                                       | 56 (100)                                 | 94, 100                                  |
| Week 4, Second Dose (unobserved at home)                     | 56                                       | 56 (100)                                 | 94, 100                                  |
| Week 8, Third Dose Primary endpoint (observed in the clinic) | 55                                       | 55 (100)                                 | 94, 100                                  |
| Weeks 4 and 8                                                | 55                                       | 55 (100)                                 | 94, 100                                  |
| Weeks 0, 4 and 8                                             | 55                                       | 55 (100)                                 | 94,100                                   |

Source: 205667 CSR Table 7.1.

1. The denominator was the number of subjects/caregivers attempting an injection at that visit. Where multiple visits were assessed, the denominator was the number of subjects/caregivers attempting an injection at all the applicable visits

2. Investigatorevaluation.

## Device usability and functionality

Responses from the usability/functionality questionnaire revealed an overall positive experience from subjects (or their caregivers) regarding the training provided by the investigator/site staff, the IFU, and the usability of the safety syringe (Table 10).

Most subjects/caregivers were comfortable with the training provided on the safety syringe and only a small number of subjects (6 subjects, 11%) requested additional guidance (review of the IFU and/or answering questions related to the IFU) prior to the unobserved, at home injection. Most subjects/caregivers found the IFU steps to be clear and understandable.

Most subjects/caregivers felt confident using the safety syringe based on the IFU and their ability, and found it easy and convenient to use. All but one of the 56 subjects questioned (98%) expressed that they  would recommend the mepolizumab liquid drug product in a safety syringe to other patients with asthma. Of the subjects previously receiving mepolizumab administered by a HCP (n=23), all but one (96%) expressed a preference for receiving mepolizumab using a safety syringe at home rather than an injection administered by a HCP.

<div style=\"page-break-after: always\"></div>

Table 10 Device Usability and Functionality Questionnaire Summary (RealWorld Use Study 205667, All Subjects)

| Response to Question                                                                                        | Number (%) of Subjects MepolizumabLiquid Safety Syringe   |
|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| n completing questionnaire                                                                                  | N=56 56                                                   |
| Very or extremely comfortable with in-clinic training provided                                              | 48 (86)                                                   |
| Requested additional guidance prior to at-home injection                                                    | 6 (11)                                                    |
|                                                                                                             | 51 (91) to 55 (98)                                        |
| Very or extremely confident using safety syringe on your own based on the IFU                               | 50 (89)                                                   |
| At the end of the study, very or extremely confident in ability to use safety syringe correctly on your own | 51 (91)                                                   |
| Safety syringe is very or extremely easy to use at home                                                     | 46 (82)                                                   |
| Very or extremely convenient to receive mepolizumab using the safety syringe at home                        | 46 (82)                                                   |
| Would recommend safety syringe to other patients with asthma   pse  n u e  s an  as                         | 55 (98) 22/23 (96)                                        |

Source: 205667 CSR Table 7.4 and Table 7.5

1. Questions were asked on various individual steps in the IFU
2. 2.C Question only asked for subjects receiving mepolizumab at baseline

## Exit interviews

Responses from the Exit Interviews conducted in a subset of subjects at selected sites (n=7) were consistent with the positive findings from the device usability/functionality questionnaire. During the interviews, subjects expressed that the text and pictures on the IFU were detailed and easy to understand, that feelings of anxiety associated with safety syringe use decreased and their confidence increased as they became more familiar with the device, and minimal to no discomfort was associated with use of the safety syringe.

## Reliability

No device failures were reported with the safety syringe device during the Real-World Use clinical study.

## Overall conclusions

- The device assessment results have shown that:
- The autoinjector and safety syringe can be correctly used by a representative population to successfully perform a self-injection procedure.
- The representative patient population and their caregivers can comprehend, learn from, and utilize the IFU to successfully administer a dose of medication.
- The IFU are understood by HCPs and are sufficient to utilize for any training that is required for their patients.
- Patients are confident with self-administration outside of the clinical setting.
- The autoinjector and safety syringe are reliable; no device failures occurred.

<div style=\"page-break-after: always\"></div>

## Summary and evaluation of Human Factors studies on the instructions for use in the Nucala leaflet.

A product-line extension for Nucala 100 mg solution for subcutaneous injection in pre-filled pen or pre-filled syringe. This medicine is administered, by 4-weekly subcutaneous (SC) injection; it may be self-administered by the patient, or administered by a caregiver, if their healthcare professional determines that it is appropriate and the patient or caregiver is trained in injection techniques.

The package leaflet (PL) for Nucala 100 mg solution for injection is supplied in a multi-part assembly, with a separate, detachable leaflet for each language. Sections 1 to 6 of the PL are printed on one side of the leaflet; on the other side are the Instructions for Use (IFU) of the device used for injection-the pre-filled pen or pre-filled syringe.

## Development and testing of the US IFU

The IFU were originally developed in the US, where-together with the relevant injection device - they were subject to usability testing, in the form of two comprehensive Human Factors Validation studies carried out and completed in April 2018. Testing was conducted in an environment designed to simulate that of a medical clinic or a home, as applicable to the participant group.

For the pre-filled pen , the study was conducted with a total of 75 participants (see below for an explanation of 'trained' and 'untrained'):

- ◆ 15 adult asthma patients-'untrained'
- ◆ 15 juvenile asthma patients-'trained'
- ◆ 15 adult COPD patients-'trained'
- ◆ 15 adult family caregivers-'untrained'
- ◆ 15 healthcare providers (HCPs)-'untrained'

For the pre-filled syringe , the study was conducted with a total of 90 participants:

- ◆ 15 adult asthma patients-'untrained'
- ◆ 30 juvenile asthma patients-15 'trained'; 15 'untrained'
- ◆ 30 adult COPD patients - 15 'trained'; 15 'untrained'
- ◆ 15 adult caregivers-'untrained''

No participant had prior experience of the IFU being tested. A minority had previously used a pre-filled pen or pre-filled syringe for injecting other products.

Participants  were  selected  across  a  wide  demographic  range,  in  terms  of  age,  education  and  other ability-affecting conditions such as visual, motor or neurological impairment.

The family caregivers were people with experience of caring for someone with any medical condition.

The HCPs were selected to represent those who might treat patients with asthma or COPD and might be responsible for training them to use the pre-filled pen or pre-filled syringe.

The study was designed to reflect as accurately as possible the circumstances in which Nucala will be used. All injections  performed  were  simulated  into  an  injection  pad  placed  over  the  injection  site  assigned  to  the participant, or placed onto a manikin for caregivers and HCPs.

<div style=\"page-break-after: always\"></div>

Caregivers and HCPs were all assigned the upper arm as injection site; other participants were assigned the abdomen or thigh, in equal numbers.

'Trained' participants (juvenile asthma patients and adult COPD patients) attended one training session, during which they reviewed the IFU and were given a verbal description of the injection procedure (but no actual demonstration). At the end of this first session, they performed one supervised injection. Approximately one week  later,  they  attended  a  second  session,  when  they  performed  one  unaided  injection,  answered comprehension and knowledge probe questions, and gave feedback on the IFU.

All  other  participants  ('untrained')  attended  a  single  session,  at  which  they  were  given  time  to  familiarise themselves with the IFU and device, then performed one unaided injection, answered comprehension and knowledge probe questions, and gave feedback on the IFU.

## Performance

For the pre-filled pen , 73 of the 75 participants (97%) were successful in injecting to achieve a full dose of Nucala.  Two  participants  lifted  the  pen  from  the  skin  early,  which  would  have  resulted  in  an  incomplete dose-one 'trained' patient was not referring to the IFU when she carried out the injection, thinking she could do it from memory; one 'untrained' caregiver did not thoroughly read the IFU before injecting. Neither failure could therefore be attributed to inadequacies in the IFU.

For the pre-filled syringe , all 90 participants (100%) successfully carried out the full injection procedure to achieve a full dose of Nucala.

There was no significant difference in performance between 'trained' and 'untrained' participants.

## Knowledge and comprehension

For  the  pre-filled  pen , there was a 99.7% success rate for correctly answering specific knowledge probe questions, demonstrating that users could correctly identify and interpret information in the IFU regarding:

- ◆ storage of the pen before use
- ◆ leaving the pen for 30 minutes to come to room temperature before injecting
- ◆ how to dispose of a used pen (US-specific)

There was a 100% success rate for comprehension of information about all stages of the preinjection and injection procedure.

For the pre-filled syringe , there was a 99.7% success rate for correctly answering specific knowledge probe questions, demonstrating that users could correctly identify and interpret information in the IFU regarding:

- ◆ storage of the pen before use
- ◆ how to inspect the solution in the pen before use
- ◆ the need to wait 30 minutes for the solution to reach room temperature
- ◆ the allowable injection sites
- ◆ how to dispose of a used pen (US-specific)

There was a 99.8% success rate for comprehension of information about all stages of the preinjection and injection procedure.

<div style=\"page-break-after: always\"></div>

## Subjective feedback

Asked for general feedback on the quality of the IFU, all participants stated that they found it easy to read, understand and follow.

## Modification of the IFU for EU markets

Some relatively minor amendments were made to the IFU for the EU PL, while preserving the essential elements of structure, design, layout and wording of the US version. This is acceptable for the CHMP.

## Conclusions and recommendations

The MAH conducted two human factor studies for the prefilled syringe and the prefilled pen. The studies enrolled adult and juvenile patients, caregivers and healthcare professional and consisted of both trained and untrained cohorts.

For the pre-filled pen, enrolled 75 patients of which 73 participants (97%) were successful in injecting to achieve a  full  dose  of  Nucala.    There  was  a  99.7%  success  rate  for  correctly  answering  specific  knowledge  probe questions, demonstrating that users could correctly identify and interpret information

For the pre-filled syringe, enrolled 90 patients, all 90 (100%) successfully carried out the full injection procedure to achieve a full dose of Nucala.

There was no significant difference in performance between 'trained' and 'untrained' participants.

There was a 99.8% success rate for comprehension of information about all stages of the preinjection and injection procedure.

To further reduce risk of incorrect administration the SPC currently states Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate and the patient or caregiver are trained in injection techniques.

## 2.4.8. Discussion on clinical efficacy

The  methodology  of  the  two  real-world  use  studies  (204959  and  205667)  is  acceptable.  The  applicant's conclusions are supported. These studies demonstrated the usability of the auto-injector and safety syringe, including self-administration outside of the clinic, in patients with severe eosinophilic asthma. The efficacy data are limited in this application however this is acceptable as it pertains to the approval of a new formulation. No major objections or other concerns are raised.

The two human factor studies were well designed and competently conducted. The results constitute sufficient validation that the Instructions For Use in the EU PL are readable, comprehensible and usable by the target user population.

## 2.4.9. Conclusions on clinical efficacy

The two real-world use studies (204959 and 205667) demonstrated the usability of the auto-injector and safety syringe, including self-administration outside of the clinic, in patients with severe eosinophilic asthma. The results of the two human factor studies can be taken to constitute sufficient validation that the IFU in the EU PL are readable, comprehensible and usable by the target user population. No further testing of the IFU for the EU PL is recommended.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Patient exposure

Mepolizumab is currently authorized as a lyophilised powder (100 mg single-dose vial), reconstituted in 1 mL of sterile  water  for  injection  prior  to  subcutaneous  (SC)  injection.  GlaxoSmithKline  (GSK)  has  developed mepolizumab as a liquid drug product which will be provided as a solution (100 mg/mL) in a prefilled syringe assembled into either a safety syringe or an autoinjector device. In this section the safety data available for liquid formulations are being discussed.  A total of 196 patients with severe eosinophilic asthma received ≥ 1 dose of mepolizumab 100 mg SC in real-world use (RWU) studies. The majority of subjects in the RWU Studies (71%) participated in only the autoinjector Study 204959 and represented a maximum of 3 months exposure. Nineteen subjects (10%) enrolled and received mepolizumab liquid drug product in both studies (Study 205667 followed by  Study  204959)  and  represented  a  maximum  of  6  months  exposure.  Demographic  and  baseline characteristics of patients enrolled to RWU studies was similar to those enrolled into the pivotal studies e.g. 60 % of subjects were females, the mean age was around 50, the majority of patients were white.

Table  1  -  Subjects  Treated  with  Mepolizumab  100  mg  SC  (RWU  Studies,  Safety  Population)

| Study                                 | Number (%) of Subjects   |
|---------------------------------------|--------------------------|
| RWU Studies, N                        | 196                      |
| Study 205667 only                     | 37 (19)                  |
| Study 204959 only                     | 140 (71)                 |
| Study 205667 followed by Study 204959 | 19 (10)                  |

Table 2 - Mepolizumab Exposure (RWU Studies, Safety Population)

|                             | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   |
|-----------------------------|--------------------------------|--------------------------------|--------------------------------|
|                             | 205667 Safety Syringe N=56     | 204959 Autoinjector N=159      | RWU Studies N=1961             |
| Treatment Exposure (months) |                                |                                |                                |
| Mean (SD)                   | 2.80 (0.219)                   | 2.78 (0.233)                   | 3.06 (0.833)                   |
| Median                      | 2.79                           | 2.79                           | 2.79                           |
| Min, Max                    | 2.0, 3.3                       | 1.0, 3.1                       | 1.0, 5.9                       |
| Range of Exposure2, n (%)   |                                |                                |                                |
| 1 month                     | 0                              | 2 (1)                          | 2 (1)                          |
| 2 months                    | 5 (9)                          | 1(<1)                          | 2 (1)                          |
| 3 months                    | 51 (91)                        | 156 (98)                       | 173 (88)                       |
| 4 months                    | NA                             | NA                             | 0                              |
| 5 months                    | NA                             | NA                             | 8 (4)                          |
| 6 months                    | NA                             | NA                             | 11 (6)                         |
| Total Subject-years3.4      |                                |                                | 49.96                          |

In addition 244 healthy adult subjects received a single dose of mepolizumab 100 mg SC in study 204958 e.g 85 subjects  received lyophilised drug product, 80 subjects received  liquid drug product in a safety syringe, and 79 subjects liquid drug product in an autoinjector.

<div style=\"page-break-after: always\"></div>

Finally 245 subjects with nasal polyposis are being treated with Mepolizumab liquid drug product or placebo in ongoing phase III randomised, double-blind, placebo-controlled study.

The Applicant confirmed that there is no post-marketing data are available for liquid formulations.

## Adverse events

## 1. 2 real-world use studies: 205667- safety syringe and 204959- autoinjector

A total of 71 subjects (36%), including 5/11 adolescents enrolled, reported on-treatment AEs, and 6 subjects (3%) reported events considered related to mepolizumab by the investigator.

Two subjects (1%) had events which led to treatment discontinuation and study withdrawal (1 subject due to an SAE of asthma and 1 subject due to 6 SAEs associated +with a road traffic accident). On-treatment SAEs were reported for 7 subjects (4%), none of which were fatal.

Table 3 - Adverse Event Summary (RWU Studies, Safety Population)

|                                                   | Number (%) of Subjects MepolizumabLiquid100mgSC   | Number (%) of Subjects MepolizumabLiquid100mgSC   | Number (%) of Subjects MepolizumabLiquid100mgSC   |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Adverse Event Type                                | 205667 Safety Syringe N=56                        | 204959 Autoinjector N=159                         | RWU Studies N=1961                                |
| Adverse events                                    |                                                   |                                                   |                                                   |
| All adverse events                                | NR                                                | NR                                                | 75 (38)                                           |
| On-treatment                                      | 17 (30)                                           | 56 (35)                                           | 71 (36)                                           |
| Drug-related2                                     | 2 (4)                                             | 5 (3)                                             | 6 (3)                                             |
| Post-treatment                                    | 0                                                 | 5 (3)                                             | 5 (3)                                             |
| Led to treatment discontinuation/study withdrawal | 1 (2)                                             | 1 (<1)                                            | 2 (1)                                             |
| Seriousadverseevents                              |                                                   |                                                   |                                                   |
| All serious adverse events                        | NR                                                | NR                                                | 8 (4)                                             |
| Pre-treatment                                     | 0                                                 | 1(<1)                                             | 1(<1)                                             |
| On-treatment                                      | 3 (5)                                             | 4 (3)                                             | 7 (4)                                             |
| Drug-related2                                     | 0                                                 | 0                                                 | 0                                                 |
| Post-treatment                                    | 0                                                 | 0                                                 | 0                                                 |
| Fatal                                             | 0                                                 | 0                                                 | 0                                                 |

AEs in the Infections and infestations SOC were the most commonly (≥3%) reported during the treatment period in the RWU Studies (20% of subjects). AEs in the Respiratory, thoracic, and mediastinal disorders SOC were the next most frequently reported (8% of subjects).

<div style=\"page-break-after: always\"></div>

Table 4 - On-treatment Adverse Events by System Organ Class (≥3% Incidence in the RWU Studies) (RWU Studies, Safety Population)

|                                                      | Number (%) of Subjects Mepolizumab Liquid 100mgSC   | Number (%) of Subjects Mepolizumab Liquid 100mgSC   | Number (%) of Subjects Mepolizumab Liquid 100mgSC   |
|------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Adverse Event System Organ Class                     | 205667 Safety Syringe N=56                          | 204959 Autoinjector N=159                           | RWU Studies N=1961                                  |
| Any event                                            | 17 (30)                                             | 56 (35)                                             | 71 (36)                                             |
| Infections and infestations                          | 9 (16)                                              | 31 (19)                                             | 39 (20)                                             |
| Respiratory, thoracic and mediastinal disorders      | 4 (7)                                               | 12 (8)                                              | 16 (8)                                              |
| General disorders and administration site conditions | 2 (4)                                               | 11 (7)                                              | 12 (6)                                              |
| Injury, poisoning and procedural complications       | 0                                                   | 12 (8)                                              | 12 (6)                                              |
| Musculoskeletal and connective tissue disorders      | 1 (2)                                               | 9 (6)                                               | 10 (5)                                              |
| Nervous system disorders                             | 0                                                   | 10 (6)                                              | 10 (5)                                              |
| Gastrointestinal disorders                           | 2 (4)                                               | 3 (2)                                               | 5 (3)                                               |
| Investigations                                       | 0                                                   | 5 (3)                                               | 5 (3)                                               |

## Common Adverse Events

The  most  commonly  (≥3%)  reported  on-treatment  AEs  in  the  RWU  Studies  were  nasopharyngitis  (5%), headache (4%), upper respiratory tract infection (4%), and urinary tract infection (3%)

Table  5  -  Common  (≥3%  Incidence  in  the  RWU  Studies)  On-Treatment  Adverse  Events  (RWU Studies, Safety Population)

|                                   | Number (%)of Subjects Mepolizumab Liquid 100 mg SC   | Number (%)of Subjects Mepolizumab Liquid 100 mg SC   | Number (%)of Subjects Mepolizumab Liquid 100 mg SC   |
|-----------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Adverse Event Preferred Term      | 205667 Safety Syringe N=56                           | 204959 Autoinjector N=159                            | RWUStudies N=1961                                    |
| Any event                         | 17 (30)                                              | 56 (35)                                              | 71 (36)                                              |
| Nasopharyngitis                   | 0                                                    | 9 (6)                                                | 9 (5)                                                |
| Headache                          | 0                                                    | 8 (5)                                                | 8 ( (4)                                              |
| Upper respiratory tract infection | 1 (2)                                                | 6 (4)                                                | 7 (4)                                                |
| Urinary tract infection           | 1 (2)                                                | 5 (3)                                                | 6( (3)                                               |

## Safety in healthy subjects - study 204958

In total, 34% of subjects reported an on-treatment AE (29%, 34%, and 38% for the lyophilised drug product, liquid drug product in an autoinjector, and liquid drug product in a safety syringe, respectively). Headache (9%), viral upper respiratory tract infection (5%) and fatigue (3%) were the most frequently reported AEs across the treatment groups.

Twenty two percent of subjects had AEs that were considered related to mepolizumab by the investigator (20%, 22%, and 25% for the lyophilised drug product, liquid drug product in an autoinjector, and liquid drug product in  a  safety  syringe,  respectively)  with  headache  (7%)  and  fatigue  (4%)  reported  most  frequently.  No on-treatment SAEs or fatal SAEs were reported during the study.

<div style=\"page-break-after: always\"></div>

Table 6 - Adverse Event Summary (Study 204958, Safety Population)

|                                         | Number (%) of Subjects Mepolizumab 100 mg SC   | Number (%) of Subjects Mepolizumab 100 mg SC   | Number (%) of Subjects Mepolizumab 100 mg SC   | Number (%) of Subjects Mepolizumab 100 mg SC   | Number (%) of Subjects Mepolizumab 100 mg SC   |
|-----------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Adverse Event Type Preferred term1      | Lyophilised N=85                               | Liquid- Safety Syringe N=80                    | Liquid- Autoinjector N=79                      | Total Liquid N=159                             | Total Mepo N=244                               |
| Any on-treatment event                  | 25 (29)                                        | 30 (38)                                        | 27 (34)                                        | 57 (36)                                        | 82 (34)                                        |
| Occurring in ≥3% of subjects2 Headache  | 6 (7)                                          | 8 (10)                                         | 9 (11)                                         | 17 (11)                                        | 23 (9)                                         |
| Viral upper respiratory tract infection | 2 (2)                                          | 6 (8)                                          | 3 (4)                                          | 9 (6)                                          | 11 (5)                                         |
| Fatigue                                 | 5 (6)                                          | 1(1)                                           | 2 (3)                                          | 3 (2)                                          | 8 (3)                                          |
| Any drug-related event3                 | 17 (20)                                        | 20 (25)                                        | 17 (22)                                        | 37 (23)                                        | 54 (22)                                        |
| Occurring in ≥1% of subjects2 Headache  | 4 (5)                                          | 7 (9)                                          | 5 (6)                                          | 12 (8)                                         | 16 (7)                                         |
| Fatigue                                 | 5 (6)                                          | 2 (3)                                          | 2 (3)                                          | 4 (3)                                          | 9 (4)                                          |
| Back pain                               | 1(1)                                           | 2 (3)                                          | 0                                              | 2 (1)                                          | 3(1)                                           |
| Diarrhoea                               | 1(1)                                           | 1(1)                                           | 1(1)                                           | 2 (1)                                          | 3 (1)                                          |
| Dizziness                               | 1(1)                                           | 2 (3)                                          | 0                                              | 2 (1)                                          | 3 (1)                                          |
| Hypersensitivity                        | 2 (2)                                          | 1(1)                                           | 0                                              | 1 (<1)                                         | 3 (1)                                          |
| AEs leading to study withdrawal         | 0                                              | 0                                              | 0                                              | 0                                              | 0                                              |
| Any SAE                                 | 1(1)                                           | 0                                              | 0                                              | 0                                              | 1(<1)                                          |
| On-treatment                            | 0                                              | 0                                              | 0                                              | 0                                              | 0                                              |
| Post-treatment4                         | 1(1)                                           | 0                                              | 0                                              | 0                                              | 1(<1)                                          |
| Fatal                                   | 0                                              | 0                                              | 0                                              | 0                                              | 0                                              |

## Serious adverse events and deaths

In the RWU Studies twelve on-treatment non-fatal SAEs were reported for 7 subjects however none of these SAEs were considered related to mepolizumab by the investigator. No deaths were reported.

No on-treatment SAEs or fatal SAEs were reported during study 204958 in healthy subjects.

## Laboratory findings

There were no apparent treatment effects on clinical chemistry, liver function tests or haematology values were seen in the RWU Studies.

## Safety in special populations

No apparent differences in the safety profile in special populations enrolled to the RWU studies were noted. Only 11 subjects in the 12-17-year subgroup participated in the RWU studies. 5 out 11 subjects reported any AE. The AEs  (PTs)  reported  by  the  12-17-year  subgroup  were  similar  to  the  other  subgroups  and  to  the  overall population. The overall incidence of on-treatment AEs was 40% in females and 31% in males, and overall AE profiles were similar for males and females. The white racial group comprised most of the population (161/196

<div style=\"page-break-after: always\"></div>

subjects) and the profile of AEs by SOC in this subgroup was similar to the overall population.  All other racial groups had few subjects.

## Immunological events

## 1. Real-world use studies: 205667- safety syringe and 204959- autoinjector

ADA assessments were conducted for all 196 subjects at Baseline and 192 subjects at Week 12/EW Visit (as applicable). Positive ADA results were reported for a total of 7 subjects (4%) at Baseline and 4 subjects (2%) at the  Week  12/EW  Visit.  Of  the  subjects  with  a  positive  ADA  result  at  Baseline  all  but  2  were  receiving mepolizumab at Screening. Of the subjects with a positive ADA result at Week 12, 1 was receiving current treatment with mepolizumab at Screening. There were 2 subjects who had positive ADA results at both Baseline and Week 12. 1 was receiving mepolizumab at Screening and the other was not. No subject positive for ADAs tested positive for neutralising antibodies. None of the 19 subjects who participated in both studies tested positive for ADAs.

One subject who was not receiving mepolizumab at Screening, tested positive at both Baseline and at the Week 12 visit, and had an increase in titre value from 16 at Baseline to 5120 at Week 12. This 40 year old female had not participated in any other mepolizumab clinical trials prior to Study 204959.

The reported current medical conditions at baseline were eosinophilic asthma, nasal polyps, sinusitis,  and hypercholesterolemia. The 1 AE reported for this subject was a non-serious event of injection site haemorrhage, of  mild  intensity  that  resolved  within  10  days.  This  subject  completed  the  study.  For  this  subject,  the mepolizumab  plasma  trough  concentration  values  remained  similar  during  the  treatment  period  with  no evidence of accumulation of drug despite repeat dosing following mepolizumab treatment initiation (204959 CSR Listing 20). There was no evidence of mepolizumab PD (blood eosinophil counts) being affected by the presence of ADAs (204959 CSR Listing 41).

<div style=\"page-break-after: always\"></div>

Table 7 - Summary of Baseline and Post-Baseline Binding ADA Assay Results (RWU Studies, Safety Population)

|                         | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   | Mepolizumab Liquid 100 mg SC   |
|-------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                         | 205667 Safety Syringe N=56     | 205667 Safety Syringe N=56     | 204959 Autoinjector N=159      | 204959 Autoinjector N=159      | RWU Studies N=1961             | RWU Studies N=1961             |
| Baseline MepolizumabUse | No                             | Yes                            | No                             | Yes                            | No                             | Yes                            |
| Week 0 (Baseline), n    | 33                             | 23                             | 75                             | 83 80 (96)                     | 108                            | 88                             |
| Negative, n (%)         | 32 (97)                        | 21 (91)                        | 74 (99)                        |                                | 106 (98)                       | 83 (94)                        |
| Positive, n (%)         | 1 (3)                          | 2 (9)                          | 1(1)                           | 3 (4)                          | 2 (2)                          | 5 (6)                          |
| Titre value, median     | 80                             | 20                             | 16                             | 8                              | 48.0                           | 8.0                            |
| Min, Max                | 80, 80                         | 8, 32                          | 16, 16                         | 8,8                            | 16, 80                         | 8,32                           |
| Week 12/EW Visit, n     | 31                             | 22                             | 74                             | 84                             | 105                            | 87                             |
| Negative, n (%)         | 30 (97)                        | 21 (95)                        | 72 (97)                        | 84 (100)                       | 102 (97)                       | 86 (99)                        |
| Positive, n (%)         | 1 (3)2                         | 1 (5)                          | 2 (3)3                         | 0                              | 3 (3)                          | 1(1)                           |
| Titre value, median     | 128.0                          | 32.0                           | 2576.0                         |                                | 128.0                          | 32.0                           |
| Min, Max                | 128, 128                       | 32, 32                         | 32, 5120                       |                                | 32, 5120                       | 32, 32                         |

Among the 4 subjects with positive ADA results at the Week 12, 2 subjects reported on-treatment AEs during the study.  On  subject  a  44  year  old  female  reported  4  AEs:  dyspepsia,  tachycardia,  fatigue  (all  of  moderate intensity), and wheezing (severe intensity); none considered related to mepolizumab by the investigator. All events occurred after the first dose, were non-serious, resolved with continued study treatment, and the subject completed the study.

## 2. Safety in healthy subjects - study 204958

ADA assessments were conducted at 5 visits during the study, Screening, Day 1 (Baseline), Day 29, Day 43, and Follow-up.

Positive ADA results were reported for 11 subjects (5%) post-Baseline: 4%, 4%, and 6% for the lyophilised drug product, liquid drug product in safety syringe, and liquid drug product in autoinjector respectively. None of whom tested positive for neutralising antibodies.

ADA measurements for 9 subjects were classified as persistent positive.

Titres were generally low, with a maximum titre of 320 observed at Study Day 29 in 1 subject treated with the liquid drug product in a safety syringe.

None of the 9 subjects with persistent positive post-Baseline ADA results reported on-treatment AEs. One of the 2 subjects  who had a transient positive ADA result on Study Day 29 (titre value: 16), reported non-serious AEs of oropharyngeal discomfort at Study Day 2 and an event of systemic reaction (hypersensitivity) with symptom of pruritus at Study Day 13 categorised as other systemic reaction by the investigator.

<div style=\"page-break-after: always\"></div>

Table 8 - Summary of ADA Confirmatory Assay Results at Baseline and at Any Post-Baseline Visit (Study 204958, Safety Population)

|                            | Number (%) of Subjects Mepolizumab100 mg SC   | Number (%) of Subjects Mepolizumab100 mg SC   | Number (%) of Subjects Mepolizumab100 mg SC   | Number (%) of Subjects Mepolizumab100 mg SC   | Number (%) of Subjects Mepolizumab100 mg SC   |
|----------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                            | Lyophilised N=85                              | Liquid-  Safety Syringe N=80                  | Liquid- Autoinjector N=79                     | Total Liquid N=159                            | Total Mepo N=244                              |
| Day 1 (Baseline), n        | 85                                            | 80                                            | 79                                            | 159                                           | 244                                           |
| Negative                   | 83 (98)                                       | 80 (100)                                      | 79 (100)                                      | 159 (100)                                     | 242 (>99)                                     |
| Positive                   | 2 (2)                                         | 0                                             | 0                                             | 0                                             | 2 (<1)                                        |
| Any post-Baseline visit, n | 84                                            | 80                                            | 79                                            | 159                                           | 243                                           |
| Negative                   | 81 (96)                                       | 77 (96)                                       | 74 (94)                                       | 151 (95)                                      | 232 (95)                                      |
| Positive1                  | 3 (4)                                         | 3 (4)                                         | 5 (6)                                         | 8 (5)                                         | 11 (5)                                        |
| Transient positive         | 1(1)                                          | 0                                             | 1(1)                                          | 1(<1)                                         | 2 (<1)                                        |
| Persistent positive        | 2 (2)                                         | 3 (4)                                         | 4 (5)                                         | 7 (4)                                         | 9 (4)                                         |
| Titre value2, median       | 16.0                                          | 256.0                                         | 32.0                                          | 32.0                                          | 32.0                                          |
| Min, Max                   | 16, 32                                        | 32, 320                                       | 8, 32                                         | 8, 320                                        | 8, 320                                        |

## Safety related to drug-drug interactions and other interactions

No formal drug interaction studies have been conducted. No new data were provided.

## Discontinuation due to AES

Two subjects (1%) were discontinued from treatment and withdrawn from the RWU Studies for the reason of AEs 1 subject due to an asthma exacerbation and 1 subject due to 6 SAEs associated with a road traffic accident. No subject was withdrawn due to AES from study 204958 in healthy subjects.

## Post marketing experience

There is no post-marketing data are available for liquid formulations.

## 2.5.1. Discussion on clinical safety

A  total  of  196  patients  with  severe  eosinophilic  asthma  received ≥ 1  dose  of  mepolizumab  100  mg  SC  in real-world use (RWU) studies. The majority of subjects in the RWU Studies (71%) participated in only the autoinjector  Study  204959  and  represented  a  maximum  of  3  months  exposure.  Nineteen  subjects  (10%) enrolled  and  received  mepolizumab  liquid  drug  product  in  both  studies  (Study  205667  followed  by  Study 204959) and represented a maximum of 6 months exposure. Demographic and baseline characteristics of patients enrolled to RWU studies was similar to those enrolled into the pivotal studies e.g. 60 % of subjects were females, the mean age was around 50, the majority of patients were white.

In addition 244 healthy adult subjects received a single dose of mepolizumab 100 mg SC in study 204958 e.g 85 subjects received lyophilised drug product, 80 subjects received liquid drug product in a safety syringe, and 79 subjects liquid drug product in an autoinjector.

<div style=\"page-break-after: always\"></div>

Finally 245 subjects with nasal polyposis are being treated with Mepolizumab liquid drug product or placebo in ongoing phase III randomised, double-blind, placebo-controlled study.

In real-world use (RWU) studies a total of 71 subjects (36%), including 5/11 adolescents enrolled, reported on-treatment AEs, and 6 subjects (3%) reported events considered related to mepolizumab by the investigator. The types of common adverse events reported during the RWU Studies were similar to those reported in the pivotal studies. The most commonly ( ≥ 3%) reported on-treatment AEs in the RWU Studies were nasopharyngitis (5%), headache (4%), upper respiratory tract infection (4%), and urinary tract infection (3%). However the data is very limited in duration and in terms of adolescents therefore longer term safety is not well documented and comparative safety to adults cannot be concluded however is not anticipated to be different.

In the RWU Studies twelve on-treatment non-fatal SAEs were reported for 7 subjects however none of these SAEs were considered related to mepolizumab by the investigator. No deaths were reported.

In a single dose study in healthy subjects on-treatment AEs were reported in 34% of subjects (29%, 34%, and 38% for the lyophilised drug product, liquid drug product in an autoinjector, and liquid drug product in a safety syringe, respectively). The type and frequency of reported AEs do not raise concern. No on-treatment SAEs or fatal SAEs were reported during this study.

Adverse events of special interest (AESI) that were prospectively identified in the severe asthma programme and remained AESIs throughout the mepolizumab clinical programme include:

-systemic (allergic [type I hypersensitivity] and other systemic) reactions,

- -local injection site reactions,
- -infections, including serious and opportunistic, malignancies,

-serious cardiac, vascular, and thromboembolic (CVT) events.

Anaphylaxis or allergic/Type I hypersensitivity was not reported in the RWU studies nor in healthy subject studies. Other type systemic reactions were reported for 12 subjects (1 in the RWU studies and 11 in healthy subject studies). All but 1 were of mild or moderate intensity. One subject who received mepolizumab liquid drug product reported the non-serious AE of drug hypersensitivity with an intensity of severe 6 days after dosing. Symptoms included fatigue, pharyngeal discomfort, swallowing difficulties, acute diarrhoea and submandibular swelling. The event had a duration of 4 days and was reported as recovered/resolved. The SmPC includes the following  statement:  Acute  and  delayed  systemic  reactions,  including  hypersensitivity  reactions  (e.g. anaphylaxis, urticaria, angioedema, rash, bronchospasm, hypotension), have occurred following administration of Nucala.

In the RWU studies 9 local injection site reactions were reported for 5 subjects (3%) including 2 adolescents. One subject, an adolescent who participated in both Study 205667 and Study 204959, reported 5 injection site reactions (3 injection site erythema and 2 injection site reaction), 2 of mild intensity and 3 of moderate.

In the heathy subjects study, events of local injection site reaction were reported for 4 subjects (2%): 1 subject in the lyophilised drug product group, 1 subject in the liquid drug product autoinjector and 2 subjects in the liquid drug product safety syringe group.

The following information is present in the SmPC for Nucala in relation to local injection site reactions: In 2 placebo-controlled studies the incidence of local injection site reactions with mepolizumab 100 mg subcutaneous and placebo was 8% and 3%, respectively. These events were all non-serious, mild to moderate in intensity and the majority resolved within a few days. Local injection site reactions occurred mainly at the start of treatment

<div style=\"page-break-after: always\"></div>

and within the first 3 injections with fewer reports on subsequent injections. The most common manifestations reported with these events included pain, erythema, swelling, itching, and burning sensation.

No serious infections, malignancy, or serious CVT events were reported.

The currently available data from the severe asthma studies indicating that mepolizumab has low immunogenic potential. In the context of the current procedure the ADA responses were investigated in the two real-world use studies where patients were treated with new liquid formulations only (205667- safety syringe and 204959autoinjector). In addition the ADA responses were investigated in study 204958 in healthy subjects where the currently approved lyophilised drug product as well as new liquid drug products were tested.

In the RWU studies the applicant investigated the antibody response at baseline and at week 12 (at end of trial visit). No assessment of ADA response at follow up was performed in the RWU studies.

In these studies the positive ADA results were reported for a total of 7 subjects (4%) at Baseline and 4 subjects (2%) at the Week 12/EW Visit. No subject positive for ADAs tested positive for neutralising antibodies. In general in the RWU studies the ADA response seems to be not greater than the ADA response observed in the originally submitted pivotal studies although the comparison between these studies is difficult e.g. a short duration of the RWU studies and the lack of the follow-up assessment is likely to underestimate the overall antibody occurrence.

One subject who was not receiving mepolizumab at Screening, tested positive at both Baseline and at the Week 12 visit, and had an increase in titre value from 16 at Baseline to 5120 at Week 12. 1 AE reported for this subject was a non-serious event of injection site haemorrhage, of mild intensity that resolved within 10 days. As indicated by the applicant no changes in PK profile of mepolizumab in this subject was reported. Such high titre value was not reported in any subject in three pivotal studies. One additional subject with the ADA positive response reported 4 AEs: dyspepsia, tachycardia, fatigue (all of moderate intensity), and wheezing (severe intensity).

In study healthy subjects (study 204958) ADA assessments were conducted at 5 visits during the study e.g. at Screening, Day 1 (Baseline), Day 29, Day 43, and Follow-up. In this study positive ADA results were reported for 11 subjects (5%) post-Baseline: 4%, 4%, and 6% for the lyophilised drug product, liquid drug product in safety syringe, and liquid drug product in autoinjector respectively. None of whom tested positive for neutralising antibodies.  ADA  measurements  for  9  subjects  were  classified  as  persistent  positive.  One  subject  with  the positive ADA response reported non-serious AEs of oropharyngeal discomfort at Study Day 2 and an event of systemic reaction (hypersensitivity) with symptom of pruritus at Study Day 13.

Based on the provided data, no apparent differences in the ADA response between lyophilised drug product and liquid drug products were noted.

AEs were reported in single patients with the positive ADA response e.g 2 subjects in the RWS and 1 subject in study 204958.

No apparent differences in the safety profile in special populations enrolled to the RWU studies were noted, although the data is quite limited. Only 11 subjects in the 12-17-year subgroup participated in the RWU studies. 5 out 11 subjects reported any AE. The AEs (PTs) reported by the 12-17-year subgroup were similar to the other subgroups and to the overall population. The overall incidence of on-treatment AEs was 40% in females and 31% in males, and overall AE profiles were similar for males and females. The White racial group comprised most of the population (161/196 subjects) and the profile of AEs by SOC in this subgroup was similar to the overall population.  All other racial groups had few subjects.

<div style=\"page-break-after: always\"></div>

The above safety data collated in the PK comparability study 204958 and Real World Use studies 204959 and 205667 with the liquid drug product give reassurance regarding the safety profile of new liquid formulation .

Comparable in-vitro biochemical and biophysical properties, together with  the same drug product specifications for the liquid and lyophilized products and comparable systemic exposure between the liquid and lyophilized drug products in the pharmacokinetic study (PK comparability study 204958) concur to provide bridge between the formulations. Overall no new safety findings were observed with the new formulation compared to the current approved lyophilized product.

## 2.5.2. Conclusions on clinical safety

No major safety issues were identified in the clinical data provided with the new formulation. The safety profile is considered comparable to the safety profile observed with the current formulation.

## 2.6. Risk Management Plan

## Safety concerns

| Important identified risks   | Systemic Allergic and Non-Allergic Reactions                                       |
|------------------------------|------------------------------------------------------------------------------------|
| Important potential risks    | Alterations in immune response (malignancies) Alterations in cardiovascular safety |
| Missing information          | Limited data in pregnant and lactating patients                                    |

## Pharmacovigilance plan

| Study status                                                                                                                                                                                  | Summary of objectives                                                                                                                                                                         | Safety concerns addressed                                                                                                                                                                     | Milestones                                                                                                                                                                                    | Due dates                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                    |
| None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          | None                                                                                                                                                                                          |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                 |
| 200870 The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in                                                                          | To evaluate outcomes for pregnant women with asthma and their infants exposed to mepolizumab                                                                                                  | Use in patients who become pregnant while taking mepolizumab.                                                                                                                                 | Final report                                                                                                                                                                                  | 2Q 2024                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| pregnancy   |
|-------------|

## Risk minimisation measures

| Safety concern                                                                   | Risk minimisation measures                                                                                                                                                                                                                                                                        | Pharmacovigilanceactivities                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety concern 1 Systemic allergic/hypersensitivity and non-allergic reactions   | Routine risk minimisation measures: The SmPC includes appropriate information in Section 4.4 (Special Warnings and Precautions) and Section 4.8 (Undesirable effects). Equivalent wording is included in the patient leaflet Section 2 and Section 4. Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : As standard across all GSK products, a targeted follow-up questionnaire is used to collect data on severe hypersensitivity/anaphylaxis. Additionalpharmacovigilance activities : None                                                                                                               |
| Safety concern 2 Potential Risk of Alterations in immune response (malignancies) | Routine risk minimisation measures: None proposed Additional risk minimisation measures None                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additionalpharmacovigilance activities: None                                                                                                                                                                                                                                                    |
| Safety concern 3 Potential Risk of Alterations in cardiovascular safety          | Routine risk minimisation measures: None proposed Additional risk minimisation measures: None                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: To further evaluate this potential risk targeted follow-up questionnaires to collect data on MI/Unstable Angina, Cerebral Vascular Accident/Transient Ischemic Attack, Deep Vein Thrombosis/Pulmonary Embolism and Peripheral Arterial Thromboembolism. Additionalpharmacovigilance activities: None |
| Safety concern 4Limited data in pregnant and lactating patients                  | Routine risk minimisation measures: The SmPCSection 4.6, Fertility, Pregnancy and Lactation, of the SmPC advises prescribers on the non-clinical reproductive toxicity data available on NUCALA. Additional risk minimisation measures: None                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additionalpharmacovigilance activities: The Mepolizumab Pregnancy Exposure Study (200870): a VAMPSS post marketing                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures   | Pharmacovigilanceactivities                           |
|------------------|------------------------------|-------------------------------------------------------|
|                  |                              | surveillance study of Mepolizumab safety in pregnancy |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 6 is acceptable.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  MAH  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.8. Product information

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: There is no need to submit a user testing for the proposed changes.

## 2.8.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Nucala (mepolizumab) is already included in the additional monitoring list.

Therefore  the  summary  of  product  characteristics  and  the  package  leaflet  includes  a  statement  that  this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Asthma is a chronic airway disease affecting approximately 334 million people worldwide and is responsible for approximately 250,000 premature deaths each year.

Asthma prevalence varies by geographical region. Accurate assessment of the prevalence of asthma has been hindered  by  varying  definitions  of  asthma  and  methods  of  data  collection,  each  combining  to  make  data comparison across studies difficult.

Risk factors include sex (gender influence varies with age), airway hyper reactivity, atopy, allergens, infections, tobacco smoke, obesity, and perinatal factors.

Asthma is common in adolescents but is frequently undiagnosed because of under-reporting of symptoms.

There  is  no  single  diagnostic  test  for  asthma,  the  diagnosis  is  a  clinical  one.  The  absence  of  consistent gold-standard  diagnostic  criteria  means  that  it  is  not  possible  to  make  unequivocal  evidence-based recommendations on how to make a diagnosis of asthma. The diagnosis of asthma in children and adults is based on the recognition of a characteristic pattern of respiratory symptoms, signs and test results and the absence of any alternative explanation for these.

Typical symptoms of asthma include periodic wheezing, chest tightness, shortness of breath, and cough, all of which worsen at night. Patients with asthma experience exacerbations of these symptoms which acutely worsen in response to various triggers such as allergens, microbes, and pollutants, resulting in significant reductions in expiratory flow as measured by forced expiratory volume in 1second (FEV).

Symptoms and signs of asthma in adolescents are no different from those of other age groups.

## 3.1.2. Available therapies and unmet medical need

The goals of chronic asthma management may be divided into two domains: reduction in impairment and reduction of risk.

Complete control of asthma is defined as:

- no daytime symptoms
- no night-time awakening due to asthma
- no need for rescue medication
- no asthma attacks
- no limitations on activity including exercise
- normal lung function (in practical terms FEV1 and/or PEF&gt;80% predicted or best)
- minimal side effects from medication.

In clinical practice patients may have different goals and may wish to balance the aims of asthma management against the potential side effects or inconvenience of taking medication necessary to achieve perfect control.

<div style=\"page-break-after: always\"></div>

Effective  asthma  management  requires  a  proactive,  preventative  approach,  similar  to  the  treatment  of hypertension or diabetes. Routine follow-up visits for patients with active asthma are recommended, at a frequency of every one to six months, depending upon the severity of asthma. These visits should be used to assess multiple aspects of the patient's asthma and to discuss steps that patients can take to intervene early in asthma exacerbations (an asthma \"action plan\"). The aspects of the patient's asthma that should be assessed at each  visit  include  the  following:  signs  and  symptoms,  pulmonary  function,  quality  of  life,  exacerbations, adherence with treatment, medication side effects, and patient satisfaction with care.

Pharmacologic treatment is the mainstay of management in most patients with asthma. The stepwise approach to pharmacotherapy is based on increasing medications until asthma is controlled, and decreasing medications when possible to minimize side effects. Adjustment of the patient's management should be considered at every visit.

The first step in determining appropriate therapy for patients who are not already on a controller medication is classifying the severity of the patient's asthma. For patients already taking one or more controller medications, treatment options are guided by an assessment of asthma control rather than asthma severity.

Specific evidence about the pharmacological management of adolescents with asthma is limited and is usually extrapolated from paediatric and adult studies.

Decreasing  therapy  once  asthma  is  controlled  is  recommended,  but  often  not  implemented  leaving  some patients over-treated.

The purpose of this line extension related to a new formulation was to seek approval for the prefilled syringe and auto injector in order to improve administration of this medicinal product.

## 3.1.3. Main clinical studies

The MAH is submitting this application to obtain marketing approval for a new drug form of a prefilled pen or syringe (mepolizumab injection, liquid drug product) of mepolizumab.  The indications currently registered for the Nucala lyophilised drug product (mepolizumab for injection) remain.

The main supportive data is obtained from the pharmacokinetic study which demonstrated bioequivalence of both new formulations to the already authorised powder for solution. Only limited efficacy data were provided as part of this application which is acceptable as it pertains to introduction of a new pharmaceutical form.

The mepolizumab liquid drug product clinical development programme consisted of 3 studies which support this application: 1 pharmacokinetic (PK) comparability study in healthy volunteers and 2 Real-World-Use (RWU) studies in subjects with severe eosinophilic asthma. All 3 studies assessed the safety profile of the mepolizumab liquid drug product.

## 3.2. Favourable effects

The PK of mepolizumab, administered subcutaneously as liquid drug product using either autoinjector or safety syringe, was shown to be statistically comparable to the PK of the commercially available lyophilized drug product.

The two real-world use studies demonstrated the usability of the auto-injector and safety syringe, including self-administration outside of the clinic, in patients with severe eosinophilic asthma.

<div style=\"page-break-after: always\"></div>

The results of the two human factor studies can be taken to constitute sufficient validation that the Instructions For Use in the EU Package Leaflet are readable, comprehensible and usable by the target user population.

## 3.3. Uncertainties and limitations about favourable effects

There are no major uncertainties. Overall, the site of injection (abdomen, thigh or arm) did not appear to markedly influence mepolizumab PK, nor the effect of mepolizumab on blood eosinophils, irrespective of device used. However, there is insufficient evidence to conclude whether there is no difference in the upper arm site of injection compared to the abdomen or thigh, since only 5 subjects in Study 204959 and 4 subjects in Study 205667 using the upper arm as a site of injection.

## 3.4. Unfavourable effects

In real-world use (RWU) studies a total of 71 subjects (36%), including 5/11 adolescents enrolled, reported on-treatment AEs, and 6 subjects (3%) reported events considered related to mepolizumab by the investigator. The types of common adverse events reported during the RWU Studies were similar to those reported in the pivotal studies. The most commonly ( ≥ 3%) reported on-treatment AEs in the RWU Studies were nasopharyngitis (5%), headache (4%), upper respiratory tract infection (4%), and urinary tract infection (3%).

In the RWU Studies twelve on-treatment non-fatal SAEs were reported for 7 subjects however none of these SAEs were considered related to mepolizumab by the investigator.

Asthma (verbatim text: asthma exacerbation) was the only SAE reported for &gt;1 subject (including 1 adolescent subject).

Six SAEs were reported for 1 subject due to a road traffic accident. None of the SAEs were considered related to mepolizumab by the investigator.

In a single dose study in healthy subjects on-treatment AEs were reported in 34% of subjects (29%, 34%, and 38% for the lyophilised drug product, liquid drug product in an autoinjector, and liquid drug product in a safety syringe, respectively).

In the RWU Studies a positive ADA results were reported for a total of 7 subjects (4%) at Baseline and 4 subjects (2%) at the Week 12/EW Visit. No subject positive for ADAs tested positive for neutralising antibodies.

In this study positive ADA results were reported for 11 subjects (5%) post-Baseline: 4%, 4%, and 6% for the lyophilised  drug  product,  liquid  drug  product  in  safety  syringe,  and  liquid  drug  product  in  autoinjector respectively. None of whom tested positive for neutralising antibodies.

## 3.5. Uncertainties and limitations about unfavourable effects

The types of common adverse reactions reported during the RWU Studies (mepolizumab injection, liquid drug product) are similar to those reported in the pivotal studies. However as the safety data are limited with the new formulation no final conclusion can be made at present and this will be monitored in the post approval setting via routine pharmacovigilance. However no differences with the known safety profile of the existing pharmaceutical form would be expected.

There was no direct comparison between the new liquid formulations tested the RWU Studies and lyophilised formulation therefor only indirect comparisons could be made. This is acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

An effect table is not appropriate in view of the clinical data submitted in this application.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The PK of mepolizumab, administered subcutaneously as liquid drug product using either prefilled pen or prefilled syringe was shown to be statistically comparable to the PK of the commercially available lyophilized drug product.

The two real-world use studies demonstrated the usability of both formulations, including self-administration outside of the clinic, in patients with severe eosinophilic asthma.

Based on the data available no major differences in relation to the safety profile between the approved lyophilised formulation and new liquid formulations formation were noted.  The types of Treatment Emergent Adverse Events reported were similar to those reported in the pivotal studies.

## 3.7.2. Balance of benefits and risks

The balance of the benefit and risks is positive for this new pharmaceutical form. The liquid formulation will add a new option in comparison with the powder for injection currently available.

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. NA.Conclusions

The overall Benefit/Risk of Nucala solution for injection in pre-filled pen and syringe is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality and safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Nucala new pharmaceutical form is favourable in the following indication:

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older (see section 5.1).

The CHMP therefore recommends the extension(s) of the marketing authorisation for Nucala subject to the following conditions:

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions regarding supply and use

## Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section

## 4.2). Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required  pharmacovigilance activities and interventions detailed in the  agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0239/2017 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

In addition, CHMP recommends the variation to the terms of the marketing authorisation, concerning the following change:

| Variation requested   | Variation requested                                           | Type            | Annexes affected    |
|-----------------------|---------------------------------------------------------------|-----------------|---------------------|
| X.02.IV               | Annex I_2.(d) Change or addition of a new pharmaceutical form | Line Extensio n | I, IIIA, IIIB and A |

<div style=\"page-break-after: always\"></div>

Extension application to introduce a new pharmaceutical form, solution for injection in pre-filled syringe or in pre-filled pen). The indication approved for this new pharmaceutical form is the same indication as the one approved for the lyophilised powder for solution for injection.